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ABSTRACT OF THE DISSERTATION
Hematopoietic Stem Cells and Progenitors in Murine Autoimmune Arthritis
by
Kwadwo Asare Oduro, Jr.
Doctor of Philosophy in Biology and Biomedical Sciences
Developmental Biology
Washington University in St. Louis, 2013
Professor Kyunghee Choi, Chairperson

Although the physiological role of stem cells in generating and maintaining a functional biological
system is widely appreciated, very little is known about the behavior of these cells in pathological
conditions. If and how these primitive cells are affected by a disease process or may contribute to
the disease process has not been adequately explored. We have studied the Hematopoietic
System, with particular emphasis on Hematopoietic Stem Cells (HSCs) and Progenitors, in a
spontaneous murine autoimmune arthritis model. We found that these mice have a systemic
increase in myeloid cells, which correlated with an increased frequency of granulocyte-monocyte
progenitors relative to other committed progenitors in arthritic marrow. Gene expression analysis
of uncommitted Kit+Sca1+Lin- (KSL) cells from arthritic bone marrow revealed increased
expression of myeloid cell related transcripts at the expense of megakaryocyte and erythroid
transcripts. In vitro, KSL cells from arthritic mice were markedly superior in generating myeloid
cells, including osteoclasts. When KSL cells from arthritic and control mice were competitively
transplanted arthritic KSL cells performed better in reconstituting the myeloid compartment.
Sustained myeloid output in vivo was environment dependent since it was abolished in young
recipients but sustained in old recipients. In these old recipients, enhanced myeloid output from
arthritic KSL cells could be detected 6 months post transplantation suggesting that the myeloid
primed state exists in the most primitive long term reconstituting HSC (LT-HSC) fraction of KSL
cells. Consistent with this, we identify a “myeloid inflammatory signature” – defined by

xii

upregulation of S100a8, S100a9, Chi3l3 and SOCS3 transcripts – that is triggered not only in
KSL cells but also to an even greater degree in prospectively sorted arthritic CD150+CD48CD34-KSL LT-HSCs. Our results indicate that primitive uncommitted progenitors of arthritic mice
are molecularly altered to have increased myeloid potential while preserving multipotentiality and
self-renewal. Since myeloid cells are critical in the inflammation and destruction that accompany
arthritis, our results further suggest that uncommitted progenitors adopt a pathologic state that
favors disease persistence. Therefore we identify the apparent existence of “inflammatory stem
cells”. This has implications for our understanding of mechanisms driving chronicity of chronic
diseases and the potential involvement of stem cells in the process.
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CHAPTER 1
INTRODUCTION

1

Physiological Maintenance of the Hematopoietic System by Hematopoietic Stem Cells
The hematopoietic system consists of a number of different mature cells with distinct
functions including oxygen transport (mediated by erythrocytes), blood clotting (mediated by
platelets) and immune defence (mediated by granulocytes, monocyte lineage cells and
lymphocytes). All these mature hematopoietic cells have a finite life span ranging from a few
hours in the case of neutrophils to months in the case of erythrocytes. Regeneration of the
hematopoietic system as mature cells die is possible because of the existence of hematopoietic
stem cells (HSCs). HSCs are cells that have the potential to give rise to all cells of the
hematopoietic system (hence “multipotential” or “uncommitted”) but also have the ability to selfrenew. Functionally, HSCs, upon transplantation, can reconstitute all hematopoietic lineages of a
lethally irradiated mice over the long term [1].
As HSCs differentiate (Figure 1), they progressively lose their self-renewal ability while
still retaining multipotentiality, giving rise to multipotential progenitors (MPPs) which lack selfrenewal ability [2]. HSCs and MPPs form a pool of uncommitted progenitors (also referred to as
“primitive progenitors” in this dissertation). As differentiatiation ensues, particular lineage
potentials are lost resulting in the formation of committed progenitors. These committed
progenitors include Common Lymphoid Progenitors (CLP), Megakaryocyte-Erythroid progenitors
(MEP) and Granulocyte-Monocyte Progenitors (GMPs). As their names suggest, CLPs have the
potential to generate only lymphoid lineages including B cells, T cells and Natural Killer cells [3-5],
MEPs generate only megakaryocytes and erythrocytes while GMPs generate only granulocytes
and monocyte lineage cells [6, 7]. Other committed progenitors like Common Myeloid Progenitors
(CMP; putative precursors of GMPs and MEPs) and lymphoid primed multipotential progenitors
(LMPPs; putative precursors of GMPs and CLPs) have been reported but also disputed [6-10].
Downstream of committed progenitors, mature cells develop via further lineage restricted
precursors For example, eosinophils develop from GMPs via eosinophil lineage committed
progenitors [11] and erythrocytes develop from MEPs via erythroid restricted precursors [7].

2

The differentiation of HSCs into mature cells, as described above, occurs primarily in the
bone marrow. Here it is thought that various cells including mesenchymal stem cells,
macrophages and possibly endothelial cells provide a niche for the HSCs [12-17]. Molecular
signals from the niche retain HSC in the bone marrow, regulate HSC quiescence, self-renewal
and differentiation and preserves HSC function over the long term. Molecular niche signals
include stromal cell derived factor-1 (SDF-1), Kit Ligand and Thrombopoietin (TPO) which interact
with CXCR4, Kit and c-Mpl respectively on HSC and primitive progenitors [18-24].

Lineage Priming and Phenotypic Identification of Hematopoietic Progenitors
Low level expression of transcripts that are abundant and/or functionally important in
mature cells is thought to underlie multipotentiality [6, 25-29]. The pattern of expression of these
transcripts is reflective of differentiation potential such that uncommitted progenitors (i.e. HSCs
and MPPs), express transcripts of all hematopoietic lineages while committed progenitors
express a more restricted lineage transcript repertoire corresponding to their downstream
progeny. This phenomenon, termed “lineage priming”, has been shown at a clonal level to be
compatible with functional properties of hematopoietic reconstitution and in vitro colony
generation [26, 30]. Similar to other stem/progenitor populations [31], HSCs also have chromatin
epigenetic modifications consistent with being poised to generate multiple lineages. Specifically,
there is the co-existence of activating histone modifications like H3K4me3 and deactivating
H3K27me3 at mature cell genes leading to low expression of these genes in the primitive cells
[32, 33]. Differentiation is coincident with the resolution of these “bivalent marks” into
predominantly activating or deactivating modifications with promotion or complete suppression of
gene expression in different progeny [31].
Although hematopoietic progenitors express mature cell mRNA to a low extent, they are
largely devoid of cell surface protein expression of a number of mature cell markers. Therefore,
all committed and uncommitted hematopoietic progenitors are phenotypically designated lineage
marker negative (or abbreviated “Lin-”) (Figure 1). To identify specific hematopoietic progenitors,
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additional markers are used. For example, primitive progenitors (HSCs and MPPs) are identified
using the marker combination Kit+Sca1+Lin- (abbreviated KSL or KLS+ to distinguish these from
committed progenitors many of which are Kit+Sca1-Lin- hence KLS-). KSL (KLS+) cells enrich
1000 fold for in vivo long term reconstituting (LT-HSC) activity compared with whole bone
marrow. HSCs within the KSL fraction can be enriched further by staining for additional markers
such as CD150, CD48, CD41 and CD34 [1, 17, 34, 35]. Since the cell numbers recoverable from
such extensive enrichment (about 0.01% of bone marrow cells) are prohibitively more difficult to
work with, KSL cells are still widely used in the study of primitive progenitors.

Primitive Progenitors in Non-physiological states – Rationale for this study
While much is known about the physiological function and properties of primitive
progenitors, knowledge of their behavior in non steady-state, including pathological conditions,
remains very limited. Hematopoietic progenitors express a number of receptors for cytokines that
are upregulated during inflammation and other non-steady states [36, 37]. These include
receptors for Interleukin 1 (IL-1), IL-3, IL-6, Granulocyte Colony Stimulating Factor (G-CSF) and
Erythropoietin among others. However, it is not clear if these cytokines exert their effects by
acting directly on primitive progenitors or on more committed progenitors. It has been shown for
instance that although 70-80% of KSL cells express the G-CSF receptor [37] the expression of
this receptor on these cells is irrelevant for their G-CSF mediated mobilization [38]. Hirai et al, has
also shown that C/EBPβ dependent emergency granulopoiesis driven by G-CSF, which is
important in combating certain infections, leads to upregulation of C/EBPβ in GMPs but not in
primitive progenitors (KSL cells) [39]. In some cases where cytokines have been shown to act on
primitive progenitors, they exert completely different effects as in the case of the platelet
producing cytokine, TPO, which acts through c-mpl to regulate HSC quiescence [23, 24].
Primitive progenitors have to strike the right balance between meeting the physiological
demand of homeostatically replenishing the hematopoietic system over the short term, while still
having enough reserve to sustain hematopoiesis over the long term. Therefore, it makes sense
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that they would be relatively protected from inflammatory signals. The relative quiescence of
primitive progenitors especially HSCs makes them relatively resistant to cell-cycle dependent
cytotoxic drugs like 5-FU [40]. Furthermore, the HSC niche contains regulatory T cells that helps
to dampen local inflammation [41]. In spite of this, recent studies have shown that various
inflammatory stimuli including those of microbial origin may lead to primitive progenitor
proliferation, expansion and functional exhaustion either directly or indirectly [42]. For example GCSF treatment of mice increases KSL frequency [43]. Alum based immunization also leads to
increased proliferation and expansion of the entire KSL compartment in an IL-1RI dependent
manner [44]. Type I and II interferon (IFN) increase proliferation of HSCs leading to expansion of
primitive hematopoietic compartments [45-48]. Polymicrobial sepsis, infection with specific
microbes such as Listeria monocytogenes, Staphylococcus aureus, Pseudomonas aeruginosa,
Mycobacterium avium as well as administration of the bacterial antigen, lipopolysaccharide (LPS)
change the cycling and/or pool size of primitive progenitors [43, 47, 49-53].
The disease relevance of these changes are however unclear for a couple of reasons.
First, a number of these studies have utilized individual cytokines or microbial agents while
disease phenomena are usually more complex involving multiple cytokines that individually may
have opposing effects. Second, while it is easy to understand how an increase in frequency or
proliferation of committed progenitors such as GMPs will consequently lead to increase in
disease relevant innate immune cells like neutrophils, it is not immediately clear how an increase
in uncommitted progenitors would lead to a specific mature cell outcome. Proliferation/Expansion
of primitive progenitors is not specific to inflammatory states as it is also seen in other situations
like increased red blood cell demand [54, 55] indicating that it may be a non-specific “knee jerk”
response to stress rather than a specific immune response. Therefore, it was important to study
primitive progenitors in a disease model and in addition to examining their cycling to also examine
their differentiation potential in the disease context.

5

KRNxG7 arthritis model
We have studied alterations in primitive progenitor homeostasis in inflammatory
conditions using a mouse autoimmune arthritis model [56, 57] (Figure 2). This model was made
by Kouskoff et al who discovered fortuitously that when transgenic mice expressing the Vα4β6
(KRN) T Cell Receptor (TCR) were crossed with NOD mice, F1 progeny (KRNxNOD or K/BxN)
spontaneously developed inflammatory arthritis with 100% penetrance [56]. The MHC II molecule
g7

I-A

in NOD mice is the key molecule for disease occurrence. Consequently while KRN on a
b

C57BL/6 (B6) background (I-A MHC II) is disease free, all offspring (hereafter referred to as
g7

KRNxG7) derived from crossing KRN mice with B6 congenic mice bearing I-A

MHC II (G7)

developed arthritis. We used KRNxG7 mice predominantly because they are more appropriate for
transplantation experiments, which are indispensable for analysis of stem cell function, since it is
free from some of the histocompatibility concerns associated with NOD mice. In our colony, joint
swelling in most KRNxG7 mice begins around 3.5 to 4 weeks of age, a little earlier than what is
reported for K/BxN arthritis which initiates around 4-5 weeks of age [58]. A few mice have
delayed onset but by 6 weeks, all mice show some degree of joint swelling. This earlier disease
onset in KRNxG7 mice may be reflective of more severe disease than in K/BxN disease because
of deficiency of complement C5 in NOD mice, a key component of disease pathogenesis [59, 60].
The mechanism of disease initiation involves the recognition, by KRN TCR on T cells, of
an epitope of the endogenous glucose phosphate isomerase (GPI) enzyme presented by the Ig7

A

MHC II molecule on antigen presenting cells [61]. During T cell development, most KRN

expressing T cells are negatively selected since they are autoreactive. However, thymic negative
selection is incomplete allowing release of autoreactive T cells and their subsequent activation
g7

[56]. Activated autoreactive T cells stimulate anti-GPI antibody production from MHC II I-A

expressing B cells in draining lymph nodes of the joint [58]. K/BxN mice with complete deletion of
Recombination Activating Gene (Rag-/-; these mice lack B and T cells), T cell receptor α chain
(Cα; these mice lack T cells) or Immunoglobulin µ heavy chain (these mice lack B cells) are
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completely resistant to disease. Furthermore, arthritis can be induced by transfer of KRN
expressing T cells into non-arthritic Cα-/-B6xG7 mice or transfer of KRN T cells plus B cells from
B6xNOD into B6xNOD Rag-/- mice [62, 63]. These results indicate that B and T cells are
required for disease initiation [62].
It is thought that the anti-GPI antibodies produced by autoreactive B cells complex with
circulating GPI and are then deposited at the joint in an FcγR dependent manner [64]. This
subsequently leads to recruitment of complement factors and cells of the innate immune system,
direct effectors of mediate joint pathology [64]. Various models have been put forward to explain
the joint specificity of this disease such as presence of unique GPI-binding molecules [65],
particularities of the vasculature facilitating inflammatory cell accumulation [66] and lack of
cellular inhibitors [67] at the joint.
Arthritis can be induced in naïve B6 mice by injecting K/BxN serum (which contains antiGPI autoantibodies) or purified anti-GPI autoantibodies [62, 68]. The serum transfer model is
widely used in studies of the mechanisms of disease since arthritis can be induced in multiple
mouse strains without the need for complicated and time consuming genetic crosses [59].
However, it is worth noting that unlike K/BxN, KRNxG7 or arthritis induced by T cell transfer,
which result sustained chronic disease, arthritis induced by serum transfer is transient with
disease peaking about 7 days after serum transfer and subsequent return to baseline.
Furthermore, the initiation stages prior to autoantibody production is not recapitulated in the
serum transfer model. Nevertheless, the ability to transfer disease to genetically unmanipulated
mice allows one to isolate effects of disease independent genetic effects. Therefore, this serum
transfer model, in addition to the KRNxG7 model, is extensively utilized in this thesis work.

Importance of Myeloid Cells in Arthritis
Although arthritis initiated by auto-antibodies [61] as described in the previous section,
myeloid cells are the direct effectors mediating joint and systemic pathologies of the disease.
Using an anti-Gr1 depleting antibody, Wipke and Allen have shown that Gr1+ cells are required
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for the joint inflammation (swelling) in arthritis [69]. Subsequent studies have corroborated the
indispensable role of neutrophils and monocyte lineages in the arthritic joint inflammation [70-74].
Osteoclasts, which are also of myeloid origin, are indispensable for the bone erosions since they
are the sole cells capable of bone resorption. In the absence of osteoclasts, joint swelling can
proceed but joint bone erosions are spared in various arthritis models [75-77].

Relevance of K/BxN or KRNxG7 arthritis model to human disease
K/BxN or KRNxG7 arthritis shares several clinical, histological and molecular features
with human rheumatoid arthritis (RA), the most prevalent autoimmune disease [78]. Clinically,
bilaterally symmetrical joint swelling with a decreasing distal to proximal involvement is
reminiscent of human RA. Histological features such as joint pannus formation, osteoclast
mediated joint erosions and consequent ankylosing and deformation of joints due to aberrant
repair are also reminiscent of human RA. This murine model also has extraarticular
manifestations/complications such as splenomegaly, lymphadenopathy and osteopenia which are
also seen in some human RA patients. Elevated levels of circulating antibodies to ubiquitous
antigens [79] are found in human RA and anti-GPI antibodies in particular is elevated in RA
patients with extra-articular complications [80]. Human RA in general and anti-GPI positive
human RA in particular are also strongly associated with MHC polymorphisms. Therefore, this
arthritis model is highly relevant to human disease and has been extensively used in teasing out
basic mechanisms in inflammatory disease.

8

REFERENCES
1.

Osawa, M., et al., Long-term lymphohematopoietic reconstitution by a single CD34low/negative hematopoietic stem cell. Science, 1996. 273(5272): p. 242-5.

2.

Morrison, S.J., et al., Identification of a lineage of multipotent hematopoietic progenitors.
Development, 1997. 124(10): p. 1929-39.

3.

Kondo, M., I.L. Weissman, and K. Akashi, Identification of clonogenic common lymphoid
progenitors in mouse bone marrow. Cell, 1997. 91(5): p. 661-72.

4.

Karsunky, H., et al., Flk2+ common lymphoid progenitors possess equivalent
differentiation potential for the B and T lineages. Blood, 2008. 111(12): p. 5562-70.

5.

Inlay, M.A., et al., Ly6d marks the earliest stage of B-cell specification and identifies the
branchpoint between B-cell and T-cell development. Genes Dev, 2009. 23(20): p. 237681.

6.

Akashi, K., et al., A clonogenic common myeloid progenitor that gives rise to all myeloid
lineages. Nature, 2000. 404(6774): p. 193-7.

7.

Pronk, C.J., et al., Elucidation of the phenotypic, functional, and molecular topography of
a myeloerythroid progenitor cell hierarchy. Cell Stem Cell, 2007. 1(4): p. 428-42.

8.

Adolfsson, J., et al., Identification of Flt3+ lympho-myeloid stem cells lacking erythromegakaryocytic potential a revised road map for adult blood lineage commitment. Cell,
2005. 121(2): p. 295-306.

9.

Boyer, S.W., et al., All Hematopoietic Cells Develop from Hematopoietic Stem Cells
through Flk2/Flt3-Positive Progenitor Cells. Cell Stem Cell, 2011. 9(1): p. 64-73.

10.

Murre, C., Defining the pathways of early adult hematopoiesis. Cell Stem Cell, 2007. 1(4):
p. 357-8.

11.

Iwasaki, H., et al., Identification of eosinophil lineage-committed progenitors in the murine
bone marrow. J Exp Med, 2005. 201(12): p. 1891-7.

12.

Omatsu, Y., et al., The essential functions of adipo-osteogenic progenitors as the
hematopoietic stem and progenitor cell niche. Immunity, 2010. 33(3): p. 387-99.

9

13.

Mendez-Ferrer, S., et al., Mesenchymal and haematopoietic stem cells form a unique
bone marrow niche. Nature, 2010. 466(7308): p. 829-34.

14.

Winkler, I.G., et al., Bone marrow macrophages maintain hematopoietic stem cell (HSC)
niches and their depletion mobilizes HSCs. Blood, 2010. 116(23): p. 4815-28.

15.

Chow, A., et al., Bone marrow CD169(+) macrophages promote the retention of
hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. Journal of
Experimental Medicine, 2011. 208(2): p. 261-271.

16.

Christopher, M.J., et al., Expression of the G-CSF receptor in monocytic cells is sufficient
to mediate hematopoietic progenitor mobilization by G-CSF in mice. Journal of
Experimental Medicine, 2011. 208(2): p. 251-260.

17.

Kiel, M.J., et al., SLAM family receptors distinguish hematopoietic stem and progenitor
cells and reveal endothelial niches for stem cells. Cell, 2005. 121(7): p. 1109-21.

18.

Fleming, W.H., et al., Steel factor influences the distribution and activity of murine
hematopoietic stem cells in vivo. Proc Natl Acad Sci U S A, 1993. 90(8): p. 3760-4.

19.

Nie, Y., Y.C. Han, and Y.R. Zou, CXCR4 is required for the quiescence of primitive
hematopoietic cells. J Exp Med, 2008. 205(4): p. 777-83.

20.

Sugiyama, T., et al., Maintenance of the hematopoietic stem cell pool by CXCL12CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity, 2006. 25(6):
p. 977-88.

21.

Czechowicz, A., et al., Efficient transplantation via antibody-based clearance of
hematopoietic stem cell niches. Science, 2007. 318(5854): p. 1296-9.

22.

Thoren, L.A., et al., Kit regulates maintenance of quiescent hematopoietic stem cells. J
Immunol, 2008. 180(4): p. 2045-53.

23.

Yoshihara, H., et al., Thrombopoietin/MPL signaling regulates hematopoietic stem cell
quiescence and interaction with the osteoblastic niche. Cell Stem Cell, 2007. 1(6): p. 68597.

10

24.

Qian, H., et al., Critical role of thrombopoietin in maintaining adult quiescent
hematopoietic stem cells. Cell Stem Cell, 2007. 1(6): p. 671-84.

25.

Hu, M., et al., Multilineage gene expression precedes commitment in the hemopoietic
system. Genes Dev, 1997. 11(6): p. 774-85.

26.

Miyamoto, T., et al., Myeloid or lymphoid promiscuity as a critical step in hematopoietic
lineage commitment. Dev Cell, 2002. 3(1): p. 137-47.

27.

Akashi, K., et al., Transcriptional accessibility for genes of multiple tissues and
hematopoietic lineages is hierarchically controlled during early hematopoiesis. Blood,
2003. 101(2): p. 383-9.

28.

Mansson, R., et al., Molecular evidence for hierarchical transcriptional lineage priming in
fetal and adult stem cells and multipotent progenitors. Immunity, 2007. 26(4): p. 407-19.

29.

Ng, S.Y., et al., Genome-wide lineage-specific transcriptional networks underscore
Ikaros-dependent lymphoid priming in hematopoietic stem cells. Immunity, 2009. 30(4): p.
493-507.

30.

Ye, M., et al., Hematopoietic stem cells expressing the myeloid lysozyme gene retain
long-term, multilineage repopulation potential. Immunity, 2003. 19(5): p. 689-99.

31.

Bernstein, B.E., et al., A bivalent chromatin structure marks key developmental genes in
embryonic stem cells. Cell, 2006. 125(2): p. 315-26.

32.

Attema, J.L., et al., Epigenetic characterization of hematopoietic stem cell differentiation
using miniChIP and bisulfite sequencing analysis. Proc Natl Acad Sci U S A, 2007.
104(30): p. 12371-6.

33.

Weishaupt, H., M. Sigvardsson, and J.L. Attema, Epigenetic chromatin states uniquely
define the developmental plasticity of murine hematopoietic stem cells. Blood, 2010.
115(2): p. 247-56.

34.

Adolfsson, J., et al., Upregulation of Flt3 expression within the bone marrow Lin()Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity.
Immunity, 2001. 15(4): p. 659-69.

11

35.

Takano, H., et al., Asymmetric division and lineage commitment at the level of
hematopoietic stem cells: inference from differentiation in daughter cell and
granddaughter cell pairs. J Exp Med, 2004. 199(3): p. 295-302.

36.

Nakauchi, H., et al., Further characterization of CD34-low/negative mouse hematopoietic
stem cells. Ann N Y Acad Sci, 1999. 872: p. 57-66; discussion 66-70.

37.

McKinstry, W.J., et al., Cytokine receptor expression on hematopoietic stem and
progenitor cells. Blood, 1997. 89(1): p. 65-71.

38.

Liu, F., J. Poursine-Laurent, and D.C. Link, Expression of the G-CSF receptor on
hematopoietic progenitor cells is not required for their mobilization by G-CSF. Blood,
2000. 95(10): p. 3025-31.

39.

Hirai, H., et al., C/EBPbeta is required for 'emergency' granulopoiesis. Nat Immunol,
2006. 7(7): p. 732-9.

40.

Arai, F., et al., Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell
quiescence in the bone marrow niche. Cell, 2004. 118(2): p. 149-61.

41.

Fujisaki, J., et al., In vivo imaging of Treg cells providing immune privilege to the
haematopoietic stem-cell niche. Nature, 2011. 474(7350): p. 216-9.

42.

Baldridge, M.T., K.Y. King, and M.A. Goodell, Inflammatory signals regulate
hematopoietic stem cells. Trends Immunol, 2011. 32(2): p. 57-65.

43.

Zhang, H., et al., STAT3 controls myeloid progenitor growth during emergency
granulopoiesis. Blood, 2010. 116(14): p. 2462-71.

44.

Ueda, Y., et al., IL-1R type I-dependent hemopoietic stem cell proliferation is necessary
for inflammatory granulopoiesis and reactive neutrophilia. J Immunol, 2009. 182(10): p.
6477-84.

45.

Essers, M.A., et al., IFNalpha activates dormant haematopoietic stem cells in vivo.
Nature, 2009. 458(7240): p. 904-8.

46.

Sato, T., et al., Interferon regulatory factor-2 protects quiescent hematopoietic stem cells
from type I interferon-dependent exhaustion. Nat Med, 2009. 15(6): p. 696-700.

12

47.

Baldridge, M.T., et al., Quiescent haematopoietic stem cells are activated by IFN-gamma
in response to chronic infection. Nature, 2010. 465(7299): p. 793-7.

48.

Hartner, J.C., et al., ADAR1 is essential for the maintenance of hematopoiesis and
suppression of interferon signaling. Nat Immunol, 2009. 10(1): p. 109-15.

49.

Scumpia, P.O., et al., Cutting edge: bacterial infection induces hematopoietic stem and
progenitor cell expansion in the absence of TLR signaling. J Immunol, 2010. 184(5): p.
2247-51.

50.

Rodriguez, S., et al., Dysfunctional expansion of hematopoietic stem cells and block of
myeloid differentiation in lethal sepsis. Blood, 2009. 114(19): p. 4064-76.

51.

Feng, C.G., et al., The p47 GTPase Lrg-47 (Irgm1) links host defense and hematopoietic
stem cell proliferation. Cell Stem Cell, 2008. 2(1): p. 83-9.

52.

Chen, C., Y. Liu, and P. Zheng, Mammalian target of rapamycin activation underlies HSC
defects in autoimmune disease and inflammation in mice. J Clin Invest, 2010. 120(11): p.
4091-101.

53.

Esplin, B.L., et al., Chronic Exposure to a TLR Ligand Injures Hematopoietic Stem Cells.
J Immunol, 2011. 186(9): p. 5367-5375.

54.

Cheshier, S.H., S.S. Prohaska, and I.L. Weissman, The effect of bleeding on
hematopoietic stem cell cycling and self-renewal. Stem Cells Dev, 2007. 16(5): p. 707-17.

55.

Li, P., et al., Regulation of bone marrow hematopoietic stem cell is involved in highaltitude erythrocytosis. Exp Hematol, 2011. 39(1): p. 37-46.

56.

Kouskoff, V., et al., Organ-specific disease provoked by systemic autoimmunity. Cell,
1996. 87(5): p. 811-22.

57.

Ma, Y.D., et al., Defects in osteoblast function but no changes in long-term repopulating
potential of hematopoietic stem cells in a mouse chronic inflammatory arthritis model.
Blood, 2009. 114(20): p. 4402-10.

13

58.

Mandik-Nayak, L., et al., Despite ubiquitous autoantigen expression, arthritogenic
autoantibody response initiates in the local lymph node. Proc Natl Acad Sci U S A, 2002.
99(22): p. 14368-73.

59.

Ji, H., et al., Genetic influences on the end-stage effector phase of arthritis. J Exp Med,
2001. 194(3): p. 321-30.

60.

Ji, H., et al., Arthritis critically dependent on innate immune system players. Immunity,
2002. 16(2): p. 157-68.

61.

Matsumoto, I., et al., Arthritis provoked by linked T and B cell recognition of a glycolytic
enzyme. Science, 1999. 286(5445): p. 1732-5.

62.

Korganow, A.S., et al., From systemic T cell self-reactivity to organ-specific autoimmune
disease via immunoglobulins. Immunity, 1999. 10(4): p. 451-61.

63.

LaBranche, T.P., et al., Characterization of the KRN cell transfer model of rheumatoid
arthritis (KRN-CTM), a chronic yet synchronized version of the K/BxN mouse. Am J
Pathol, 2010. 177(3): p. 1388-96.

64.

Wipke, B.T., et al., Staging the initiation of autoantibody-induced arthritis: a critical role for
immune complexes. J Immunol, 2004. 172(12): p. 7694-702.

65.

Studelska, D.R., et al., High affinity glycosaminoglycan and autoantigen interaction
explains joint specificity in a mouse model of rheumatoid arthritis. J Biol Chem, 2009.
284(4): p. 2354-62.

66.

Binstadt, B.A., et al., Particularities of the vasculature can promote the organ specificity of
autoimmune attack. Nat Immunol, 2006. 7(3): p. 284-92.

67.

Matsumoto, I., et al., How antibodies to a ubiquitous cytoplasmic enzyme may provoke
joint-specific autoimmune disease. Nat Immunol, 2002. 3(4): p. 360-5.

68.

Maccioni, M., et al., Arthritogenic monoclonal antibodies from K/BxN mice. J Exp Med,
2002. 195(8): p. 1071-7.

69.

Wipke, B.T. and P.M. Allen, Essential role of neutrophils in the initiation and progression
of a murine model of rheumatoid arthritis. J Immunol, 2001. 167(3): p. 1601-8.

14

70.

Chen, M., et al., Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J
Exp Med, 2006. 203(4): p. 837-42.

71.

Kim, N.D., et al., A unique requirement for the leukotriene B4 receptor BLT1 for
neutrophil recruitment in inflammatory arthritis. J Exp Med, 2006. 203(4): p. 829-35.

72.

Jonsson, H., P. Allen, and S.L. Peng, Inflammatory arthritis requires Foxo3a to prevent
Fas ligand-induced neutrophil apoptosis. Nat Med, 2005. 11(6): p. 666-71.

73.

Scatizzi, J.C., et al., p21Cip1 is required for the development of monocytes and their
response to serum transfer-induced arthritis. Am J Pathol, 2006. 168(5): p. 1531-41.

74.

Solomon, S., et al., A crucial role for macrophages in the pathology of K/B x N seruminduced arthritis. Eur J Immunol, 2005. 35(10): p. 3064-73.

75.

Pettit, A.R., et al., TRANCE/RANKL knockout mice are protected from bone erosion in a
serum transfer model of arthritis. Am J Pathol, 2001. 159(5): p. 1689-99.

76.

Redlich, K., et al., Osteoclasts are essential for TNF-alpha-mediated joint destruction. J
Clin Invest, 2002. 110(10): p. 1419-27.

77.

Redlich, K., et al., Tumor necrosis factor alpha-mediated joint destruction is inhibited by
targeting osteoclasts with osteoprotegerin. Arthritis Rheum, 2002. 46(3): p. 785-92.

78.

Kyburz, D. and M. Corr, The KRN mouse model of inflammatory arthritis. Springer Semin
Immunopathol, 2003. 25(1): p. 79-90.

79.

Monach, P.A., et al., A broad screen for targets of immune complexes decorating arthritic
joints highlights deposition of nucleosomes in rheumatoid arthritis. Proc Natl Acad Sci U
S A, 2009. 106(37): p. 15867-72.

80.

van Gaalen, F.A., et al., Association of autoantibodies to glucose-6-phosphate isomerase
with extraarticular complications in rheumatoid arthritis. Arthritis Rheum, 2004. 50(2): p.
395-9.

15

Figure 1. Physiological Generation of the Hematopoietic System from Primitive
Progenitors
Primitive/Uncommitted Progenitors consists of Hematopoietic Stem Cells (HSCs), which have
self-renewal ability, and Multipotential Progenitors (MPPs), which have lost self-renewal ability.
They generate the committed progenitor pool which consists of Megakaryocyte Erythroid
Progenitors (MEP), Granulocyte Monocyte Progenitors (GMP) and Common Lymphoid
Progenitors (CLP). Cell cycling is directly related to maturity of progenitors so that HSCs are most
quiescent while commited progenitors are most cycling. Committed progenitors generate mature
cells. Mature cells express mature lineage markers and are thus designated Lineage Marker + (or
Lin+). Progenitors, both committed and uncommitted, lack expression of these markers and are
thus Lin-. Primitive progenitors are identified as Kit+Sca1+Lin-.
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Figure 2. Arthritis Models used in this study
Arthritis models utilized in this study are boxed in red.
Spontaneous Chronic Arthritis: KRN TCR transgenic mice crossed with C57BL/6.G7 (G7) mice
g7

which have the class II MHC molecule I-A

generates KRNxG7 progeny which all develop

arthritis spontaneously. Joint swelling usually begins around 3.5-4 weeks of age and peaks
around 6 weeks of age. The disease remains chronic.
Induced Transient Arthrits (Serum Transfer Arthritis): Serum from the chronic model can be
transferred to naïve mice to induce a transient arthritis that peaks about 1 week after injection
followed by complete resolution.
Induced Chronic Arthritis: T cells transferred to T cell deficient (Cα-/-) B6xG7 mice induces
arthritis which peaks about 2 weeks after transfer and remains chronic.
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CHAPTER 2
GENERAL CHARACTERIZATION OF HEMATOPOIESIS IN ARTHRITIC MICE

Part of the contents of this chapter has been published in a co-authored manuscript (Ma Y et al,
2009. Blood 114:4402). To differentiate my work from that of others, I only cite this publication in
this chapter when it refers to work done by others
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OVERVIEW
Very little is known about primitive progenitors in non-steady state conditions especially in
a disease model. To study primitive progenitors in a disease model we have chosen the KRNxG7
model of autoimmune arthritis. In this chapter we present analyses of frequencies of progenitors
and mature cells in arthritic and control mice that form the basis for subsequent analyses
presented in chapters 3 and 4. The significant findings from this chapter are that although BM
primitive progenitor frequency is similar in arthritic bone marrow, frequencies of committed
progenitors and mature cells are markedly changed in favor of myeloid lineages. We also
demonstrate an increase in splenic primitive progenitors in arthritic mice that are unlikely due to
immigration from the bone marrow, challenging the prevailing dogma for initiation of
extramedullary hematopoiesis in adult spleen.

PRIMITIVE PROGENITOR FREQUENCY ANALYSIS
Similar Bone Marrow Primitive Progenitor Frequency and Turnover
Various genetic mutations and inflammatory stimuli cause an expansion or decline in
primitive progenitor frequency often accompanied by changes in proliferation status. To address
the question of whether primitive progenitors are perturbed in arthritic mice, we examined the BM
KSL frequency before (1-3 week old) and during (6 week and older) signs of visible disease
(Figure 1A). BM KSL frequency was unchanged in young arthritic mice (1 week, 3 weeks, 6-9
week old). The frequency of CD150+CD48-CD41 (hereafter “SLAM HSC”) cells, which analyzes
a more purified HSC population [1], was also similar between arthritic and control mice. Slight
increase in KSL frequency of arthritic mice as they got older (15-20 weeks old) was not
associated with a change in SLAM HSC frequency indicating that HSC frequency is unchanged
even at these ages.
To determine if arthritis leads to changes in proliferation of primitive progenitors, we
assessed the fraction of KSL cells that had incorporated the administered nucleotide analog
bromodeoxyuridine (BrdU) in replicating DNA (Figure 1B). BrdU injected 2-3 hours before
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sacrificing mice is taken up by cells and incorporated into new DNA synthesized during this
period. Therefore, BrdU+ fraction gives the fraction of cells traversing S-phase during the period
of exposure to the BrdU reagent. Consistent with previous reports [2], we found that KSL cells
from young mice (4 week old) had a higher BrdU+ fraction than KSL cells from 6-8 week or 16
week old mice (Figure 1B and Data Not Shown). KSL (or KLS+) cells also cycled less (lower
BrdU+ fraction) than Kit+Sca1-Lin- (KLS-) cells, which contain committed progenitors and hence
are less primitive and more proliferative [3]. Within this KLS- population, MEPs cycle more
frequently than GMPs [3] which may account for the lower BrdU+ fraction of arthritic KLS- cells;
arthritic mice have increased GMP to MEP ratio in the BM (see later – Figure 7). However at no
time point did we see a significant difference between BrdU+ fraction of the primitive progenitor
enriched KSL (KLS+) cells from KRNxG7 versus age matched control mice.
Administered BrdU could itself induce cell cycling [4] although it was unlikely based on
the dose we used. We were also concerned about the bioavailability of injected BrdU in arthritic
mice versus controls. Therefore, we also assessed cell cycling by a different approach that does
not depend on administration of exogenous agents. Ki67 is an intracellular molecule expressed
by all cycling cells regardless of the stage, while non-cycling, quiescent, G0 cells are Ki67
negative [5]. As an internal control, we verified that KLS- committed progenitors were less
quiescent than KSL cells and that KSL cells from young (3 week old) mice were more proliferative
than KSL cells from older (6-8 week old) mice (Data Not Shown). KSL cells are heterogeneous
with only about 5% being long term self renewing HSCs. It was possible that cycling in arthritic
HSCs was changed even if bulk KSL cell cycling was not changed. Therefore, we examined Ki67
expression in CD150+CD48-KSL cells, which are highly enriched in HSC activity (at least 1 out of
2 cells [1]) in addition to Ki67 expression of total KSL cells. Consistent with their primitive status in
both arthritic and control mice, about 70% of CD150+CD48-KSL cells were Ki67

neg

compared with

about 15-20% of KSL cells (Figure 1C-F). We however detected no difference in Ki67

neg

fraction

when comparing the same population from arthritic and control mice consistent with our BrdU
results.
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Therefore unlike in a number of inflammatory states, primitive progenitor frequency and
cycling is unchanged in arthritic mice. This is consistent with the similar ability of KRNxG7 arthritic
and B6xG7 control bone marrow to rescue lethally irradiated mice in serial transplantation
experiments (Yunglin Ma, [6]). It is however worth noting that total BM cellularity is increased
about 50%, implying that absolute primitive progenitor counts are also increased in arthritic mice.
We checked for differences in apoptosis by annexin V mediated recognition of cell surface
phosphatidylserine staining. However, only a very small fraction (about 2%) were annexin V+ in
both arthritic and control KSL cells with no difference between the two strains (Data Not Shown).
Highly efficient clearance of apoptosing cells in vivo [7] may however obscure accurate evaluation
of KSL cell apoptosis in arthritic and control mice.

Increased Primitive Progenitors in Arthritic Spleen
HSC frequency was similar in arthritic marrow despite the fact that arthritic bones had an
osteoblast deficiency resulting in low bone formation rate and low-turnover osteoporosis [6]. This
was unexpected because osteoblasts have been proposed as putative niche cells for HSCs [8, 9].
Previous studies had indicated that suppression of osteoblast activity with G-CSF or conditional
ablation of osteoblasts by ganciclovir treatment of Collagen 2.3 promoter driven thymidylate
kinase transgenic mice (Col2.3-TK) resulted in splenic extramedullary hematopoiesis (EMH) [1012]. Therefore, we examined the spleen and found that although HSC frequency was similar in
arthritic and control bone marrow, KSL and SLAM HSC frequencies were markedly higher in 6
week old arthritic spleens compared with age matched control spleens (Figure 2A & 2B). This
was corroborated by transplantation experiments showing superior rescue of lethally irradiated
recipients by Lin- cells from arthritic spleen than Lin- cells from control spleens (Yunglin Ma, [6]).
To determine how early increased primitive progenitors occur in the spleen, we examined
the spleens of young KRNxG7 mice prior to disease (joint swelling) onset (i.e.1-3 wk old) and age
matched controls. KRNxG7 KSL and SLAM HSC frequencies were similar to control mice at 1-3
weeks of age supporting the fact that increased splenic primitive progenitors occur after initiation
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of joint swelling or is coincident with it (Figure 2A & 2B). However, both KSL and SLAM analyses
yielded different results. KSL frequency in 6 week old KRNxG7 arthritic spleen was similar to KSL
frequency in 2 week old KRNxG7 and age matched controls (0.15-0.3%); what was different was
the drastic reduction of KSL cells in 6 week old control spleen by an order of magnitude (Figure
2A). SLAM HSC frequency on the other hand was the same in 8 week old control mice as it was
in 3 week old KRNxG7 and control mice (0.001-0.004%); what was different was a drastic
increase in SLAM HSC in 8 week old arthritic spleens (about 0.04%) (Figure 2B).
During normal ontogeny of the hematopoietic system, the main site for hematopoiesis
shifts from the fetal liver to the bone marrow starting from late gestation. In the early days of life,
hematopoietic activity is pronounced not just in the bone marrow but also in the liver and spleen
[13, 14]. As mice grow, the primitive progenitors in extramedullary sites including the spleen
disappear and the bone marrow becomes the major site for hematopoiesis. The decreased
splenic KSL frequency in 6 week old non arthritic mice compared with 1wk or 2wk old mice
(Figure 2A) reflects this normal ontogenic process. In contrast, the maintenance of splenic KSL
frequency in 6 week old arthritic KRNxG7 mice at levels similar to KSL frequency in the neonatal
stage suggested that there was disruption of normal ontogenic decline of splenic progenitors in
arthritic mice. In other words, do primitive progenitors increase in spleen by a passive mechanism
of persistence of primitive progenitors or by a more active process of accumulation as the SLAM
HSC frequency analysis (Figure 2B) would suggest?

Increased splenic primitive progenitors can be induced by T cell transfer arthritis but not
by serum transfer arthritis
To address the mechanism of increased primitive progenitor frequency in spleens of
arthritic mice, we induced arthritis in wild type mice at 2.5-3 months of age. Wild type mice at this
age have negligible splenic progenitors. We reasoned that splenic progenitors will increase upon
arthritis induction if this occurred by an “active” process such as immigration of HSCs from the
bone marrow, decreased emigration of constitutively circulating HSCs from spleen and/or

22

proliferation of resident HSCs in the spleen. However, if spleen progenitors are high in arthritic
mice due to disrupted ontogeny, as explained in the previous section, then arthritis induction in
2.5-3 month old wild type mice, which have already undergone ontogenic decline of splenic
progenitors, would fail to recapitulate this phenotype.
We injected 2.5-3 month old B6 mice with repeated doses of arthritogenic serum to
trigger a sustained arthritis as done previously [15] (Figure 2C). We confirmed that these mice
developed arthritis based on joint swelling. However, at no time point during the course of the
experiment did we detect a significant increase in splenic KSL cells, even 6 weeks post the initial
injection (Figure 2D). In contrast, we found that arthritis induction by KRN T cell transfer into Cα-/B6xG7 mice [16] elicited a close to 10-fold increase in splenic KSL frequency (Figure 2D).
Therefore, splenic primitive progenitors are actively induced during arthritis development
and not just passively retained from the neonatal period. Arthritis per se is insufficient for the
splenic progenitor increase since splenic KSL frequency remains at a very low level in serum
transferred arthritic mice. Rather, increased KSL cells are associated with early events in arthritis
initiation prior to anti-GPI secretion since these events are recapitulated in the T cell transfer
model but not in the serum transfer model. These early events include activation of autoreactive T
cells and B cells. Activated T cells have been reported to regulate the frequency of primitive
hematopoietic progenitors in the spleen [17, 18] and future work can address how T cell
activation participates in the augmentation primitive progenitors in arthritic spleens.

Splenic primitive progenitors likely increase by expansion of in situ progenitors rather
than mobilization from the bone marrow
Inflammatory stimuli like G-CSF, LPS or Pertussis Toxin (PTX) and conditional ablation of
osteoblasts can mobilize hematopoietic progenitors from the bone marrow [10, 19-22]. In the
cases of G-CSF and LPS treatment, these lead to EMH that has been shown to result from the
increased emigration of BM progenitors [19, 20]. Recently it has also been suggested that EMH
could also result from inflammation driven impaired egress of constitutively circulating progenitors
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transiting extramedullary organs [23]. Therefore, it was possible that increased primitive
progenitors in arthritic spleen were derived from the bone marrow either by increased mobilization
or impaired egress from the spleen. We found that peripheral blood (PB) KSL frequency was
increased in PB of KRNxG7 arthritic mice (Figure 3A) rendering impaired egress an unlikely
mechanism for increased splenic progenitors; impaired egress should result in decreased or
similar PB KSL frequency.
Increased splenic progenitors could also result from expansion of the few progenitors that
normally reside in the spleen at steady state. The spleen is the most prominent extramedullary
localization of progenitors in adult mice. At steady state, there are about 700 colony forming units
of progenitors (CFU) in the spleen; compared with 10000-20000 in the bone marrow of a single
femur or about 100 in the liver [23]. Monette et al showed that the increase in splenic CFU activity
that occurred following immunization of mice with killed Bordetella pertussis consisted of a
hydroxyurea sensitive period of proliferating and expanding splenic progenitors prior to a
hydroxyurea insensitive immigration of progenitors [24]. The early part of the expansion phase
was associated with a rise in PB CFU activity and a dip in BM and spleen CFU activity indicating
that the spleen is not simply a reservoir that only receives progenitors from the bone marrow in
response to inflammatory stimuli.
Therefore either mobilization or expansion or both were plausible mechanisms for
expansion of splenic progenitors in arthritic mice. To test whether mobilization of primitive
progenitors contributes to the increased primitive progenitors in arthritic spleens we generated
asplenic mice. We reasoned that if arthritic spleens siphoned off mobilized primitive progenitors
then PB primitive progenitors would increase in the absence of a spleen. We generated
genetically asplenic KRNxG7 arthritic mice (KRNxG7 Tlx1-/-). Tlx1 (Hox11) is a transcription
factor that specifies splenic development during embryogenesis. Tlx1-/- mice are viable with the
only prominent defect being the absence of spleen unlike other asplenic mice that have a
multitude of defects [25, 26]. We also surgically splenectomized KRNxG7 mice at 3 weeks old
and compared their PB KSL frequency to that of sham operated mice at 8 weeks of age.
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Genetically (Tlx1-/-) and surgically splenectomized KRNxG7 mice developed arthritis similar to
KRNxG7 mice with intact spleen (Figure 3B and Data Not Shown).
Like B6xG7 non arthritic control mice, asplenic B6xG7 mice had very low PB KSL
frequency (Figure 3C). More importantly we found that PB KSL frequency in asplenic KRNxG7
mice (Tlx1-/- and surgically splenectomized mice were pooled) was not changed compared with
KRNxG7 mice having an intact spleen (Figure 3C). BM KSL frequency was not changed either so
cells destined for the spleen were not “backed up” in the BM (Figure 3D). In the absence of
compensating mechanisms like translocation of progenitors to other extramedullary sites [27] or
increased apoptosis, these data (Figure 3C & 3D) suggest that mobilization from the bone
marrow likely plays a minimal role in the increased splenic primitive progenitors in arthritis. This
result contrasts with G-CSF or LPS treatment of splenectomized mice which both result in
augmentation of PB hematopoietic progenitors following splenectomy confirming BM to spleen
mobilization of progenitors by these factors [19, 20].

Increased splenic progenitors in arthritic spleen is independent of TNFα signaling
Physiological retention of primitive progenitors in the bone marrow is mediated by SDF1/CXCR4 interaction and a number of molecules that mobilize BM primitive progenitors do so by
downregulating SDF-1, CXCR4 or by blocking their interaction [11, 22, 28-30]. TNFα which is
upregulated in human arthritis and in our arthritic mice (Changwon Park, [6]) is capable of
downregulating BM SDF-1 leading to mobilization of osteoclast precursors in arthritis [31-33].
TNFα also mobilizes B cell precursors to the spleen as occurs in alum immunization [34].
Furthermore, TNFα inhibits osteoblastogenesis [35] and promotes osteoclast activation [36] both
conditions that have been reported to promote mobilizaton of BM progenitors [10, 37]. Therefore
we hypothesized that blocking TNFα signaling in arthritic mice would block mobilization of
primitive progenitors; the sensitivity of splenic primitive progenitors would indicate whether this
pathway is involved in accumulation of splenic primitive progenitors.
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To test this, we blocked TNFα signaling in KRNxG7 arthritic mice by 2 approaches.
Firstly we treated a cohort of KRNxG7 mice with anti-TNFα antibody [38] and a control cohort
with anti-GST antibody continuously for 3 weeks starting from 3 weeks of age (Figure 3E). In the
second approach, we generated KRNxG7 mice lacking the proinflammatory TNF receptor TNFRI
(p55) [39]. The p55 receptor mediates the pro-osteoclastogenic [36, 40] as well as antiosteoblastogenic effects of TNFα [35]. Consistent with previous reports [41, 42], these TNFα
deficient mice still developed arthritis. However, we failed to see any significant differences in
splenic KSL frequency nor colony formation (Figure 3F & 3G) indicating that absence of TNFRI
does not impair accumulation of splenic progenitors.

Summary of Primitive Progenitor analysis
Therefore in summary, primitive progenitor frequency and cell cycling is unchanged in
arthritic bone marrow while it is increased in the peripheral blood and spleen. The increase in
primitive progenitors in the spleen is unrelated to the peripheral blood changes and likely results
from expansion of the few resident progenitors that remain in the spleen during development. The
mechanism of expansion is associated with early events in arthritis initiation prior to antibody
generation and activated T cells may be involved.

MATURE CELL AND COMMITTED PROGENITOR FREQUENCY ANALYSIS
To determine the mature cells output in arthritic mice we examined bone marrow, spleen
and peripheral blood for frequency of myeloid cells (Gr1+), B lymphoid cells (B220+) and T
lymphoid cells (CD3+). We found a systemic increase in Gr1+ cells and a decrease in the
lymphoid populations (Figure 4A). We also noticed that long bones of arthritic mice and bone
marrow suspensions retrieved from these mice were pale (Figure 4B). Since the red color of
normal bone marrow is due to erythrocytes this observation suggested that red blood cells (RBC)
were depleted in arthritic marrow and that arthritic mice were consequently anemic. Peripheral
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blood complete blood counts (CBC) confirmed that arthritic mice were mildly anemic compared
with controls (Figure 4C). RBC counts, RBC volume and consequently hemoglobin amount were
all decreased in arthritic peripheral blood indicating a microcytic anemia. RBC Distribution Width,
a measure of anisocytosis is increased. Therefore, arthritic mice have microcytic anemia with
increased anisocytosis, which are clinical signs of “anemia of chronic disease”. We next
examined the changes to the leukocyte populations further.

Defective Bone Marrow B lymphopoiesis in arthritic mice
In the bone marrow B220+ cells can be divided into more mature/recirculating B220

hi

lo

cells which are also IgM+ and immature B220 cells which are also AA4.1+ [43, 44]. We found
hi

that the residual B220+ cells in arthritic bone marrow were almost all B220 IgM+AA4.1- with
lo

almost complete depletion of B220 IgM-AA4.1+ (Figure 5A). PreB, ProB and PreproB cells,
which represent increasingly more immature B cell precursors contained within the B220+IgMpopulation, were all depleted in arthritic marrow (Figure 5B). The fact that frequency of mature
and immature subsets of B220+ cells were differentially affected in arthritic mice implied that the
diminished B220+ frequency was not simply an artifact of increased Gr1+ frequency.
This B lymphopoiesis defect occurred in the context of osteoblast deficiency in arthritic
mice [6]. Previous studies have also reported that manipulation of osteoblasts lead to B
lymphopoietic defects implicating osteoblasts in normal development of B lymphocytes [10, 45,
46]. For example, Wu et al, showed that deleting Gsα in osteoblast lineage cells using Osterix
Cre caused reduction in the B lymphopoietic cytokine, IL-7, and a B cell defect at the level of
ProB cells [46]. Zhu et al, also showed that conditional ablation of mature osteoblasts by
ganciclovir treatment of Col2.3 TK transgenic mice led to a more severe depletion of B cells at
the pre-pro B level with concomitant reduction SDF-1 and Flt3L in addition to IL-7 [45]. Therefore,
we examined production of B lymphopoietic cytokines in the marrow and found reductions in
SDF-1 (Changwon Park, [6]), Flt3L and IL-7 as well (Figure 5C). A recent study has however
suggested that the main SDF-1, Flt3L and IL-7 producing cells in the bone marrow are not bone-
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building osteoblasts but stromal cells dispersed in the marrow [47]. Consistent with this we found
that expression of these cytokines were not changed in 3 week old KRNxG7 mice (Figure 5D)
even though osteoblast deficiency had already begun with reduction in osteoblast and osteoclast
markers (Figure 5E & 5F).

Arthritic marrow is myeloid skewed
We also examined the increased Gr1+ cells in the bone marrow of arthritic mice further.
As expected most of these Gr1+ cells co-stained with Mac1 thus confirming they are indeed
myeloid cells rather than other cells like T cells and plasmactyoid dendritic cells that have also
been reported to be Gr1+ [48, 49]. Two populations of Mac1+Gr1+ cells could be distinguished
hi

based on level of Gr1 expression. Gr1 cells, which are mature neutrophils, were of similar
frequency in arthritic and control marrow (Figure 6A). Mean frequencies differed by less than 20%
and rarely reached significance. On the other hand the increased overall Gr1+ frequency was
lo

most pronounced in the Gr1 subset. Mac1+Gr1lo frequency was 100-200% increased in arthritic
marrow (Figure 6A).
This population has been reported to contain monocytes [50] as well as immature
hi

neutrophils – promyelocytes and myelocytes [51-53]. Consistently, whereas Mac1+Gr1 cells
expressed high levels of the neutrophil marker Ly6G (detected with antibody clone 1A8),
Mac1+Gr1lo cells expressed lower and heterogeneous levels of Ly6G (Figure 6B). On the other
lo

hand, Mac1+Gr1 uniquely contained cells expressing the monocyte specific c-Fms.molecule and
expressed higher levels of FcγRIII/IIb, Ly6C and the chemokine receptors Ccr1 and Ccr2
important in monocyte trafficking and in osteoclastogenesis [54-56] (Figure 6B, 6C and data not
hi

shown). Both monocytes (defined as Mac1+Gr1lo cFms+Ly6C ) and immature neutrophils
int

(defined as Mac1+Gr1lo cFms-Ly6C ) are increased in arthritic marrow although the magnitude
of the increase is slightly greater for the latter (Figure 6C and Data not shown). Macrophages
(defined as F480+Gr1loMac1+ cells) were also elevated in arthritic marrow (Figure 6D).
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Therefore the increased myeloid output in arthritic mice is not restricted to a particular type of
myeloid cell.

Myeloid skewing in arthritic marrow is evident at the committed progenitor level
Myeloid cells, lymphoid cells and RBCs are derived from different committed progenitors
– GMP, CLP and MEP respectively. The fact that increased BM Gr1+ and decreased BM B220+
were most pronounced in more immature subsets (Mac1+Gr1lo and B220+AA4.1+ respectively)
suggested that the increased myeloid cells and reciprocally decreased lymphoid and erythroid
cells in arthritic marrow was developmentally regulated. Therefore we examined committed
progenitors to determine if myeloid skewing existed at this level. GMPs and MEPs are both
contained within the Kit+Sca1-Lin-IL7Rα- fraction of the bone marrow. We found a skewing
hi

towards increased FcγRIII/IIb CD34+ GMPs and decreased FcγRIII/IIb-CD34- MEPs (Figure 7A).
The degree of skewing seemed to correlate with clinical severity of disease since it was more
pronounced in mice that were more emaciated, less mobile and had more brittle bones (data not
shown). Furthermore, we found that Flk2+IL7Rα+Lin- cells which contain CLPs and B cell
committed progenitors that are more immature than any B220+ expressing cell fraction [57, 58]
was completely depleted in arthritic marrow (Figure 7B). Frequency of Lymphoid primed
multipotential progenitors (LMPPs), a subset of KSL cells with myeloid and lymphoid potential but
no erythroid potential [59, 60] and hence presumptive precursors of CLPs and GMPs, was
unchanged (Figure 7C). Therefore, arthritic marrow have increased myeloid cells and committed
myeloid progenitors at the expense of lymphoid and erythroid cells and their committed
progenitors.

Erythroid and B lymphoid lineage cells are expanded in distinct extramedullary sites
The peripheral anemia in arthritic mice is not as severe as would be predicted based on
bone marrow analysis presumably due to partial compensation by splenic erythropoiesis. We
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found enhanced splenic erythropoiesis in arthritic mice with increased CD71+ erythroid
precursors (Figure 8A). This is reminiscent of “stress erythropoiesis” that is triggered by a variety
of anemia inducing conditions such as irradiation or phenylhydrazine treatment [61, 62].
Megakaryocytes (CD41+CD61+ cells), which are also derived from MEPs were also increased in
arthritic spleen (Figure 8B). Therefore it appears while the bone marrow of arthritic mice is
inhospitable to the differentiation of MEP and downstream progeny, differentiation into these cells
in the spleen is not impaired. Alternatively, the primitive progenitors in arthritic spleen have a
different lineage potential from the primitive progenitors in arthritic bone marrow.
The diminished B220+ cells in KRNxG7 mice was paradoxical because this arthritis
model is antibody mediated and it has been reported that K/BxN mice have high amounts of
circulating immunoglobulins [15, 63]. Previous studies have suggested that immunization,
infection, and inflammatory cytokines can mobilize B-cell precursors into the periphery [34, 52,
64]. Therefore, we conducted further analysis on spleen and lymph node to determine whether B
lymphopoiesis is relocated to other sites, which might account for the increased IgG in serum of
arthritic mice. We found a 10-fold increase in B cell derived plasma cell frequency in the spleen
despite the fact that splenic B220+ frequency was decreased (Figure 8C). We also found that
unlike in other organs examined, frequency of B cells and B cell precursors were increased in
arthritic lymph nodes (Figure 8D & 8E).
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Figure 1. Frequency and Proliferation of primitive progenitors in arthritic (KRNxG7) bone
marrow is unchanged
A. Flow cytometry determined Bone marrow (BM) primitive progenitor frequency of KRNxG7
and control mice of different ages.
1 week (wk) KSL: 2 KRNxG7 mice and 4 control (B6xG7) mice were used.
3 wk KSL: Data is pooled from 2 experiments with total of 9 KRNxG7 and 9 control (G7 and
KRN) mice.
6-9 wk KSL: Data is pooled from 5 experiments with total of 26 KRNxG7 and 24 control (G7,
B6xG7, KRN, B6xKRN) mice.
15-20 wk KSL: Data is pooled from 3 experiments with total of 13 KRNxG7 and 13 control
(B6xG7, KRN) mice.
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7-8 wk CD150+CD48-CD41-: 4 KRNxG7 and 7 control (B6xG7, B6xKRN) were used.
14-16 wk CD150+CD48-CD41-: 4 KRNxG7 and 3 control (B6xG7) were used.
B. Flow cytometry determined BrdU+ fraction of KLS+ cells (primitive progenitors; same as KSL
cells, highlighted with red box) and of KLS- cells (committed progenitors) in arthritic and age
matched control bone marrow. 3-5 mice in each group were analyzed at each time point. 6-8
week analysis is pooled from 2 independent experiments. B6 mice were used as controls for
6-8 week analysis. KRN mice were used as control for 16 week analysis.
C. FACS plots depicting Ki67 analysis of KSL cells.
D. Representative FACS plots depicting gating scheme for analysis of quiescent fraction of
CD150+CD48-KSL IL7Rα- cells (HSCs) in bone marrow of arthritic and control mice based
on intracellular Ki67 expression. An isotype control antibody (Top panel) aided in setting the
Ki67 negative gate.
E. Most KSL cells (dark grey solid histogram) are Ki67+ (non quiescent). However most KSL
CD150+CD48- cells (colored histograms) from both arthritic and control mice are Ki67(quiescent). Light grey/hatched histogram represents isotype control.
F. Quantification of Ki67 negative (quiescent) fraction of HSCs.
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Figure 2. Primitive progenitor frequency is increased in KRNxG7 arthritic spleen and can
be induced by T cell transfer arthritis
A. Flow cytometry determined splenic KSL frequency in KRNxG7 mice and age matched
controls.
1 week (wk): 2 KRNxG7 mice and 4 control (B6xG7) mice were used.
2 wk: 6 KRNxG7 mice and 3 control (B6xG7) mice were used. KRN control mice gave similar
results as B6xG7 controls (not shown).
6 wk: Data is pooled from 2 experiments. 11 KRNxG7 mice and 7 control (B6xG7, G7) mice
were used. At 6 weeks, Arthritic KSL cells are also increased relative to KRN controls (N=8,8
pooled from 2 experiments) although the fold change is less (Not Shown). KRN controls
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seem to have higher basal splenic KSL cells and Gr1+ cells than non-TCR transgenic control
mice (Data Not Shown).
B. Flow cytometry determined splenic CD150+CD48-CD41 (“SLAM HSC” frequency in KRNxG7
and control mice. 3wk: 5 KRNxG7 and 5 control (B6xG7) mice were used. 8wk: 4 KRNxG7
and 3 control mice were used. As for KSL analysis SLAM HSC frequency is also increased
relative to KRN control at 8 weeks (N=4 KRN, 3 KRNxG7) but the fold difference is less as
KRN spleens have more SLAM HSCs than non TCR transgenic controls (Not shown).
C. Experimental scheme for testing induction of splenic progenitor increase by arthritogenic
serum transfer into B6 mice. The first serum injection is administered on Day 0 (D0). Dose of
serum (or PBS) administered on different days post the initial injection is indicated in black.
Days post initial injection when cohorts of mice are sacrificed for analysis are indicated in
blue.
D. Flow cytometry determined Splenic KSL frequency at different days post initial serum or PBS
injection (dpi). None of the differences are statistically significant
E. FACS plots illustrating Induction of splenic KSL frequency by KRN T cell transfer into T cell
deficient Cα-/- B6xG7 mice to cause arthritis. Control mice are Cα-/- B6xG7 mice that were
not given exogenous T cells.
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Figure 3. Increased primitive progenitors in arthritic spleen likely occurs by expansion of
resident splenic progenitors rather than by mobilization
A. Flow cytometry determined PB KSL frequency in KRNxG7 and age matched controls. 610wk: Data is pooled from 2 experiments. 7 KRNxG7 and 7 control (G7, B6xG7) mice were
used. 17-18wk: 4 KRNxG7 and 4 control (B6xG7) mice were used.
B. Absolute Weight and Mean ankle thickness trajectories after surgical splenectomy or sham
surgery of 3 week old KRNxG7 mice. Each line (and number) corresponds to an individual
mouse. 8 mice were splenectomized but only 4 are shown. #4464 never developed arthritis
as evinced by continuous weight gain and ankle thickness that remains relatively constant.
The trajectory of this mouse is similar to the trajectory of wild type control mice (Not shown).
C. Flow cytometry determined PB KSL frequency in peripheral blood of 7-10 week old KRNxG7
and B6xG7 mice with or without spleens. B6xG7 mice without spleens are all genetically
asplenic (Tlx1-/-). 2 KRNxG7 mice without spleens are genetically asplenic (Tlx1-/-) while the
remaining 3 were surgically splenectomized. 1 KRNxG7 mouse with a spleen underwent a
sham surgical operation; the rest are un-operated. Each dot represents an individual mouse.
Data is pooled from 3 experiments. PB KSL
D. Flow cytometry determined BM KSL frequency of 7-10 week old KRNxG7 mice from Figure
3C above.
E. Experimental scheme for administration of α-TNFα neutralizing antibody or anti-GST control
antibody to arthritic mice.
F. Left: Flow cytometry determined splenic KSL frequency
Right: Methylcellulose colony formation from total spleen
Of KRNxG7 arthritic and control mice following treatment with α-TNF-α neutralizing antibody
or an α-GST control
G. Flow cytometry determined splenic KSL frequency in KRNxG7 arthritic and B6, G7 or B6xG7
control mice with or without the TNFα Receptor I (TNFRI)
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Figure 4. Reciprocal expanded myeloid cells and diminished lymphoid cells in arthritic
mice
A. Flow cytometry determined frequency of myeloid (Gr1+), B lymphoid (B220+) and T lymphoid
(CD3+) in bone marrow, spleen and PB of 6-8 week old arthritic (KRNxG7) and control mice.
Control mice used were KRN for spleen and G7 or B6xG7 for BM and PB mice. Gr1+ cells in
spleen is higher in KRN controls than in TCR non transgenic controls. Mac1+F480+
macrophage frequency in the spleen is also shown. Shown is the mean for 3 to 11 mice
analyzed per strain for each tissue.
B. Top Panels: Bone marrow pellet from arthritic and control mice.
Bottom Panel: Marrow suspensions from tibiae and femur of control and arthritic mice.
Red color is indicative of red blood cell content in bone marrow. Arthritic bone marrow pellet
is paler indicating a relative deficiency of red blood cells in the marrow.
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C. Erythrocyte parameters in Peripheral blood CBC confirming mild anemia in arthritic mice.
RBC = RBC count, MCV=Mean Corpuscular Volume, MCH=Mean Corpuscular Hemoglobin
Amount, MCHC=Mean Corpuscular Hemoglobin Concentration, RDW=Red Blood Cell
Distribution Width. 2 male and 2 female of control and arthritic mice were used. This
experiment was repeated with identical results with N=5 mice in each group.

Figure 5. Defective marrow B lymphopoiesis and associated bone microenvironment
changes
A. Representative FACS plot for B220+ cells in BM of KRNxG7 arthritic or G7 control mice.
Whole bone marrow is stained for B220 and AA4.1 (a marker for B-cell precursors). B-cell
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precursors (B220loAA4.1+; arrow) are virtually depleted in KRNxG7 BM, whereas most of the
residual cells are B220hi and IgM+ (IgM staining not shown).
B. Flow cytometry determined frequencies of B220+IgM- B cell precursors in the BM. From least
mature to most mature: PreproB (B220+IgM-CD19-CD43+NK1.1-CD11c-), ProB (B220+IgMCD19+CD43+), PreB (B220+IgM-CD19+CD43-), and B cells (B220+IgM+).
C. Expression of various B lymphopoiesis promoting cytokines in 6 week old arthritic (KRNxG7)
and control (G7) marrow. Expression was determined by quantitative real-time PCR (qRTPCR), followed by normalization to GAPDH. IL-7 (Interleukin 7), Flt3-L (ligand for Flk2).
D. QRT-PCR of B lymphopoiesis promoting cytokines in 3 week old KRNxG7 and B6xG7 control
marrow. SDF-1 (Stromal Cell Derived Factor -1)
E. QRT-PCR of osteoblast related genes in 3 week old KRNxG7 and B6xG7 control marrow.
Runx2 is a transcription factor required for early steps in osteoblastogenesis. OSC
(osteocalcin), OPG (osteoprotegerin) and RANKL are all produced by osteoblasts.
F. QRT-PCR of osteoclast specific genes in 3 week old KRNxG7 and B6xG7 control marrow.
Cath K (Cathepsin K).
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Figure 6. Myeloid skewing in arthritic bone marrow
A. Left Panel: Representative FACS plots of Mac1 and Gr1 stained bone marrow (BM) with
gated Mac1+Gr1lo and Mac1+Gr1hi populations (red gates).
Right Panel: Mean frequency and standard deviation of BM Mac1+Gr1lo and Mac1+Gr1hi
populations.
B. Flow cytometry histograms depicting expression of FcγRIII/IIb and Ly6G (detected with
antibody clone 1A8) on Mac1+Gr1lo and Mac1+Gr1hi cells of KRNxG7 arthritic and control
mice. The expression of these markers on Mac1-Gr1- cells of a non-arthritic control mouse is
also shown (green histogram) to serve as a basis for comparison
C. Top Panel: Representative FACS plots showing Mac1+Gr1lo cells (See Figure 1a)
subfractionated based on expression of cFms and Ly6C. cFms+Ly6C+ cells (red gate) are
monocyte lineage cells. The remaining cFms-Ly6Clo (blue gate) are therefore enriched in
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immature neutrophils (promyelocytes, myelocytes) which are also Mac1+Gr1lo. Bottom
lo

Panel: Quantification of subpopulations of Mac1+Gr1 .
D. Top Panel: FACS plot of F480 versus Gr1 of bone marrow cells. Bottom Panel: Quantification
lo

of F480+Gr1lo cells as a fraction of Mac1+Gr1 cells and as a fraction of total bone marrow
live cells. 4 arthritic mice and 4 control mice were used.

Figure 7. Myeloid skewing in arthritic marrow is evident at the committed progenitor level
E. Top Panel: Representative FACS plot for analysis of BM committed progenitors. GMPs and
MEPs are FcγRIII/II+CD34+ (red gate) and FcγRIII/II-CD34- (blue gate) respectively within
Kit+Sca1-Lin-IL7Rα- cells.
Bottom Panel: GMP and MEP frequencies normalized to total Lin-IL7Rα- myeloerythroid
progenitors. GMP analysis is pooled from 3 independent experimental sets total of 10 mice
per each group. MEP analysis is pooled from 2 independent experimental sets with 7 mice
per each group.
G. Top Panel: Representative FACS plot depicting depleted CLP (purple gate) in KRNxG7 bone
+

+

−

marrow. CLPs are identified as Flk2 IL-7Rα Lin .
Bottom Panel: CLP frequency analysis.

47

H. Frequency of Lymphoid primed multipotential progenitor (LMPP; Kit+Sca1+Lin-Flk2hiCD34+)
in the bone marrow

Figure 8. Erythroid and B lineage cells are increased in distinct extramedullary sites
A. FACS plots indicating CD71 and Ter119 expression of cells of RBC lysed spleen from
arthritic and control mice. In addition to RBC lysis this plot is pre-gated using forward scatter
and side scatter parameters that exclude the most mature red blood cells. Increased
hi

lo

hi

frequency of immature RBC lineage cells including Ter119 cells and Ter119 CD71 (both
gated) indicates robust erythropoiesis in arthritic spleens. Arthritic spleens also had increased
MEP frequency (not shown).
B. Mean splenic CD41+CD61+ frequency and standard deviation. CD41+CD61+ phenotypically
identify megakaryocytes. Together with Figure 5C above supports increased activity of MEP
in arthritic spleens unlike their depletion in arthritic marrow.
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C. Representative FACS plots and bar graphs of plasma cells in spleens of control and arthritic
mice. Splenocytes that were not myeloid cells nor T cells (CD3-Mac1-) but expressed the
plasma cell marker CD138 (syndecan-1) at high levels were identified as plasma cells.
D. Mean frequencies of various B lineage populations in lymph node (LN). Frequencies shown
are total B220+ cells and subsets of these cells from least mature to most mature – preproB,
proB, preB (all B220+IgM-) and B220+IgM+ cells. Frequencies of all subsets of B220+ cells
are increased in arthritic lymph nodes.
lo

-/lo

E. Mean frequencies of total progenitors (Lin-) and B lymphoid progenitors (Kit Sca1 LinIL7Rα+) in arthritic and control lymph node (LN). Both total Lin- and B lymphoid progenitor
frequencies are increased in arthritic LN. B220 is included in the “Lin” cocktail and hence
these cells are B220-, even more immature than the B cell precursors examined in Figure 8D.
To exclude T cells from the Lin- gate, CD3 was used.

49

CHAPTER 3
CELL INTRINSIC MOLECULAR DIFFERENCES BETWEEN ARTHRITIC AND CONTROL
PRIMITIVE PROGENITORS

Most of the contents of this chapter has been published in Oduro KAJ et al, 2012. Blood
120:2203
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OVERVIEW
Our preliminary analysis of primitive progenitors in arthritic mice (Chapter 2) revealed that
the frequency and cycling of these cells in the bone marrow are unchanged compared with age
matched non-arthritic controls. In contrast we demonstrated marked differences in the frequency
of various mature cells and the committed progenitors that give rise to them in the bone marrow.
Specifically, we found that myeloid cells and GMPs were increased while lymphoid cells,
erythrocytes and their respective committed progenitors – CLPs and MEPs – were decreased in
arthritic marrow.
In this chapter, we take this analysis a step further by asking the question - Is the
increased GMPs and myeloid cells in arthritic mice at the expense of other lineages due to
changes at primitive progenitor level not revealed by frequency or cell cycle analyses? As our
analysis in Chapter 2 illustrates, it is possible that the skewed myelopoiesis in arthritic marrow is
simply a consequence of relocation of erythroid and lymphoid progenitors to other organs. Ueda
et al has suggested that marrow myeloid and lymphoid development share a common
developmental niche such that mobilization of B lymphoid precursors out of the bone marrow by
alum immunization for example reallocates spatial resources for myeloid development [1]. Altered
turnover rates of the different committed progenitors in arthritic mice could also affect abundance
of the committed progenitors and consequently their mature progeny.
All these potential explanations invoke possible mechanisms for myeloid skewing that do
not depend on any cell intrinsic contributions from primitive progenitors. Therefore to determine
whether uncommitted progenitors are involved in the myeloid skewing we decided to sort these
cells and analyze them prospectively. We demonstrate in this Chapter, cell intrinsic molecular
differences between primitive progenitors obtained from arthritic and non-arthritic control mice.
These differences suggest that primitive progenitors are myeloid primed by the arthritic
environment.
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MYELOID PRIMING IN ARTHRITIC PRIMITIVE PROGENITORS

KSL cells from KRNxG7 arthritic mice upregulate myeloid genes and downregulate
erythroid genes
The KSL phenotype contains all primitive progenitors and enriches about 1000 fold for
the HSC activity compared with whole bone marrow. The similar cell cycling of KSL cells from
KRNxG7 arthritic and control mice (Chapter 1) indicated that this phenotype identified a similar
population in arthritic and control mice that is different from the faster cycling committed
progenitors [2]. We sorted Kit+Sca1+Lin- (KSL) cells from arthritic and control mice to high purity
(Figure 1A). To verify the immaturity of KSL cells from both arthritic and control mice, relative to
committed progenitors i.e. GMPs, we cultured sorted KSL cells and GMPs in methylcellulose
media containing various hematopoietic cytokines. Although both KSL cells and GMPs formed
colonies in the presence of myelopoietic cytokines, KSL cells had superior plating efficiency than
GMPs as well as bigger colonies indicating greater per cell output (Figure 1B & 1C). In the
presence of erythropoietic cytokines, only KSL cells formed colonies (Figure 1B). KSL cells but
not GMPs also survived in B lymphopoietic culture media (See Chapter 4). Therefore, KSL cells
from KRNxG7 arthritic mice just like control KSL cells are uncommitted – unlike GMPs, which are
committed since they lack the capacity to thrive in erythroid or lymphoid restricted media.
To determine cell intrinsic molecular differences that might exist between arthritic and
control KSL populations, we compared their transcriptomes using mouse Affymetrix 430 2.0
microarray. This array uses about 45000 probesets to assess the abundance of over 39000
transcripts. We have previously shown that stem cell enriched populations, transient amplifying
progenitor populations and mature cell populations are distinguishable based on gene ontology
(GO) analysis of genes enriched in the population [3, 4]. Using a similar analysis we confirmed
that KSL cells from arthritic and control mice cluster together and with other stem cell enriched
populations from previous studies (Figure 1D). In fact, out of over 45000 probesets assayed, only
about 700 (1-2%) detected transcripts that were differentially regulated in arthritic versus control
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KSL cells. We reasoned that the identity of these differentially regulated genes and more
importantly their associated functions will indicate how arthritic KSL cells differ from control KSL
cells.
Therefore we performed in silico functional annotation of the differentially regulated
genes using DAVID Bioinformatics – an online genome anaylsis resource that integrates several
in silico analysis tools [5]. We found that functional annotation categories such as “cell surface”
-7

-6

(7X enriched; p=1.5x10 ), “transmembrane protein” (5X enriched; p=1.7x10 ) were significantly
enriched in genes downregulated in arthritic KSL cells but not in the upregulated genes (Figure
2A & not shown). Interestingly the few cell surface/ transmembrane protein genes that were
upregulated in arthritic KSL cells included several receptors for inflammatory cytokines such as
IL6st (gp130) and IL17Rα (Figure 2B).
We specifically inquired whether lineage specific genes were differentially regulated in
arthritic KSL cells. We found increased expression of the C/EBP family of myeloid transcription
factors - C/EBP α, β and δ - and other myeloid associated genes (Figure 2C & 2D). On the other
hand a number of erythroid and megakaryocyte genes including key transcription factors like
GATA1, EKLF (Klf1), Fog1 (Zfpm1) and Gfi1b were downregulated in arthritic KSL cells (Figure
2E). To validate these microarray results, we analyzed expression of 24 genes, including some
upregulated and downregulated genes from the microarray, using quantitative real time PCR on
KSL cells from arthritic and control mice that were independent from the pools used for the
microarray. As an internal control we verified that the sorted KSL cells expressed much lower
levels of the GMP markers FcγRIII and FcγRIIb than sorted GMPs (Figure 3A). We also verified
that arthritic KSL and control KSL cells expressed similar levels of the cell cycle inhibitor and
stemness gene p21 [6] (Figure 3B). Out of 24 genes assessed, expression of 18 was changed in
a manner consistent with the microarray experiment (Figure 3C & data not shown). Notably we
were able to validate the increased expression of highly myeloid specific genes like S100a8 and
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Chi3l3 as well as decreased expression of key erythropoietic transcription factors like Gata1 and
EKLF.
We also detected increased cell surface protein expression of FcγR III/IIb on arthritic KSL
cells (Figure 3D) consistent with upregulation of FcγRIII and FcγRIIb transcripts from the
microarray analysis (Figure 2D). During normal myelopoiesis FcγR III/IIb cell surface expression
is upregulated at the GMP level and is sustained in mature cells. In fact, FcγR III/IIb is used as a
marker for myeloid committed progenitors, GMPs [7, 8]. The level of FcγRIII/IIb cell surface
protein and mRNA expression in arthritic KSL cells were much less than on GMPs (Figure 3A &
3D) thus implying that arthritic KSL cells are not misidentified GMPs but rather bonafide KSL cells
on a path towards myeloid differentiation.

Induction of the “myeloid Inflammatory signature” by arthritogenic serum transfer
g7

Since mice having both KRN transgene and MHC II IA

always develop arthritis, our

non-arthritic control mice are always genetically different from the KRNxG7 arthritic mice in terms
g7

of lacking either the KRN transgene or the arthritogenic MHC II IA

allele. It is theoretically

possible although unlikely that the myeloid biased gene expression pattern we observed in
KRNxG7 arthritic KSL cells was a consequence of genetic differences with control mice. To
determine if this myeloid bias was indeed arthritis environment dependent, we utilized the serum
transfer model of arthritis [9]. Naïve C57BL/6 wild type mice when injected with serum from
arthritic mice, develop arthritis that peaks around day 7. These serum induced arthritic mice also
have relatively increased GMPs and Mac1+Gr1lo cells in the bone marrow compared to PBS
injected controls (Figure 4A & 4B). We sorted KSL cells from serum transfer and PBS injected
mice and performed qRT-PCR analyses. Again, KSL cells from serum transfer arthritic mice
expressed higher levels of the myeloid specific genes Chi3l3, S100a8, S100a9, SOCS3 and
lower levels of key erythropoietic transcription factors GATA1 and Fog1 than PBS injected
controls (Figure 4C) recapitulating what we saw in KRNxG7 arthritic KSL cells.
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The gene expression pattern of serum transfer KSL cells and KRNxG7 KSL cells were
not identical though. For instance C/EBPβ and Ccr2, which were increased and EKLF, which was
decreased in KRNxG7 KSL cells (Figure 3C) were not changed in the serum transfer KSL cells
(Figure 4C). These differences may represent changes that require prolonged duration of arthritis
since the serum transfer model only induces a transient arthritis. In fact the mild (30-40%)
lo

increase in bone marrow Mac1+Gr1 frequency (Figure 4A) in the serum transfer model is similar
to KRNxG7 mice at the very early stages of disease prior to joint swelling (i.e. 3-week old; Figure
4D); it is unlike the 100-200% increase in the frequency of this population in KRNxG7 mice with
full blown disease (Chapter 2; Figure 6). The gene expression differences may also be due to
differences in disease severity. Unlike the KRNxG7 mice where all distal limb joints are affected,
disease development in the serum transfer model is more heterogeneous with some distal limb
joints spared [9]. Not all joints were affected in the cohort of serum transferred mice used for the
gene expression analysis. Furthermore, in our experience, mice with serum transfer arthritis do
not appear as sick clinically (i.e. they are not emaciated and their bones are not brittle unlike
KRNxG7 arthritic mice). They also lack the marked increase in peripheral blood Mac1+Gr1+ cells
seen in KRNxG7 arthritis mice (Chapter 2: Figure 4 and Data Not Shown).
Nevertheless our data shows that the myeloid primed state of KRNxG7 KSL cells is
arthritis dependent since we can induce key molecular expression changes in KSL cells of mice
after just 7 days of arthritis exposure. We refer to upregulation these genes – SOCS3, S100a8,
S100a9 and Chi3l3 – as a “myeloid inflammatory signature” based on consistent induction in both
KRNxG7 and serum transferred arthritic mice.

“Myeloid Inflammatory Signature” Genes are upregulated in Primitive HSCs
Only about 5% of KSL cells are true HSCs. It was of interest to know if the myeloid
priming we observed in KSL cells also existed at this level. These cells have self-renewal
capability and for this reason can replenish the hematopoietic system over the long term.
Therefore myeloid priming at this level might be of significance in terms of understanding chronic
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inflammation. Previous studies have shown that all long term reconstituting HSC (LT-HSC)
activity is contained within the CD150+CD48-CD34- fraction of KSL cells [10, 11]. Specifically 4050% of CD150+CD48-KSL [11] and 40% of CD34-KSL cells [12] have LT-HSC activity in single
cell transplantation experiments implying that CD150+CD48-CD34-KSL represents a highly
enriched LT-HSC population.
We prospectively sorted CD150+CD48-CD34-KSL cells from arthritic and control mice
and performed a gene expression analysis. We found that although the expression of a number
of transcription factors (TF) was unchanged (Figure 5A), all the myeloid genes constituting the
myeloid inflammatory signature identified earlier – SOCS3, S100a8, S100a9 and Chi3l3 – were
increased in arthritic HSCs compared with control HSCs (Figure 5B). In fact the magnitude of the
increase at the HSC level was greater than the fold increase at the bulk KSL level (Figure 5C). . It
is worth noting that myeloid committed progenitors (i.e. GMPs) are CD150- and CD34+ [7, 8, 13]
making it even more unlikely that the myeloid inflammatory signature we have identified is due to
contamination by GMPs.
TF activity can be increased by mechanisms other than increased expression such as
post-translational modification or subcellular localization. Future work can address if these other
mechanisms rather than increased expression of myeloid TFs or decreased expression of
erythroid TFs explain the markedly enhanced transcriptional activity at myeloid genes in HSCs.
In summary, activation of a myeloid program by the arthritic environment is initiated at the
most primitive HSC level.

FEATURES OF NORMAL AGING IN ARTHRITIC KSL CELLS
How might such lineage-biased transcription be compatible with a primitive progenitor
status? We mentioned earlier that only 2% of probe sets were differentially regulated in KSL cells
from KRNxG7 arthritic KSL cells versus control KSL cells and only a fraction of these could be
considered lineage specific genes. Furthermore for most differentially regulated genes the
changes were modest – less than 3 fold. To determine if the changes observed at the mRNA
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level are generally also reflected at the protein level we performed FACS analysis of a number of
differentially regulated genes using KSL cells. Proteins which are typically expressed on the cell
surface were chosen due to relative ease of assessment compared with cell permeabilization to
access intracellular proteins. In contrast with what we showed for FcγR III/IIb earlier (Figure 3D),
13 out of 17 genes changed at the mRNA level including all the cytokine receptors assayed were
not changed at the cell surface protein level (Figure 6 and Data not shown). Although changes to
intracellular protein levels for these and other genes is possible, these data support the idea that
primitive progenitors are thrust in a state of “readiness” (i.e. “primed”) that is measured
presumably to avoid compromising their primitive progenitor status.
Two of the genes whose protein expression we were able to confirm were explored
further because of their previously association with normal aging – another epigenetic state
where myeloid potential is increased in primitive progenitors.

Elevation of IgG and P selectin proteins in arthritic KSL cells
Three probe sets corresponding to P selectin and 4 probe sets corresponding
immunoglobulin heavy chain (IgH) were increased in KRNxG7 arthritic KSL cells relative to both
KRN and B6xG7 non-arthrtic control KSL cells (Figure 7A). In fact IgH transcripts, together with
transcripts of the myeloid gene Chi3l3, were the most upregulated in arthritic KSL (about 10 fold
upregulated); all 4 IgH probe sets were in the top 5 upregulated “microarray hits”. Previous
studies have found that P selectin mRNA and protein are upregulated in primitive progenitors in
aged (21-28 month old) mice relative to younger mice [14, 15]. Chambers et al found that while
only about 3% of KSL side population (SP) cells in 2 month old mice are P selectin positive, about
81% of these cells were P selectin positive in 28 month old mice [14]. We checked and confirmed
that consistent with our microarray result, P selectin protein was increased in arthritic KSL cells
even though these cells were obtained from mice that were only 6-8 weeks old (Figure 7B).
Therefore, similar to normal aging, KSL cells in KRNxG7 arthritis upregulate P selectin.
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Presence of IgH in KSL cells is unusual because, physiologically, immunoglobulins are
associated with B lineage cells. Furthermore at steady state, the earliest progenitors to display
VDJ recombinase activity, which is a pre-requisite for immunoglobulin production, are CLPs [16].
Although IgH transcripts have previously been reported in KSL cells using the same microarray
platform (Mouse 430 2.0) that we utilized in our study [17], and are upregulated by normal aging,
[14] these transcripts have been considered “sterile”, resulting from aberrant transcprition of non
recombined IgH loci that consequently do not code for any protein [14, 17].
To gain further insight into the upregulated IgH transcript in arthritic KSL cells, we first
determined which specific IgH transcripts were upregulated in arthritic KSL cells. Examination of
the target sequences recognized by all 4 affymetrix IgH probe sets (Figure 7A) revealed that they
th

were partially overlapping and all mapped to the 4 exon of the IgG1 constant region gene (Cγ1)
(Figure 7C & 7D). To determine if full-length Cγ1 transcript was upregulated in uncommitted
progenitors in arthritis, we performed qRT-PCR experiments on independently sorted cells using
primer sets designed to recognize exons 1, 2 and 3 of Cγ1 (Figure 7E). As expected, Cγ1
transcripts were virtually undetectable in KSL cells or highly purified HSCs (CD150+CD34-CD48KSL) cells sorted from control animals. However, levels of Cγ1 was markedly upregulated in
arthritic KSL cells and even more so in purified HSCs regardless of the primer sets used (Figure
7F). These results suggested that there is upregulation of full length Cγ1 transcript, not just
fragments, in primitive progenitors, including HSCs, in arthritic mice.
To determine if these transcripts were sterile or were translated, we examined cell
surface immunoglobulin protein expression on KSL cells by flow cytometry. Consistent with
previous reports, we were unable to detect any immunoglobulin on the surface of KSL cells from
young wild type mice (Figure 7G). KSL cells from KRNxG7 arthritic mice expressed cell surface
IgG, but not IgM, the first immunoglobulin synthesized during physiologic B cell development.
(Figure 7G and Data Not Shown). Furthermore, we found using monoclonal to different IgG
isotypes that the surface IgG detected on arthritic KSL cells was specifically of the IgG1 isotype
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(Figure 7G), consistent with our transcript analysis. This phenomenon was arthritis dependent
because a similar pattern of cell surface IgG1 protein expression was detected on KSL cells from
wild type B6xG7 mice induced to develop arthritis by serum transfer (Figure 7H). Interestingly,
KSL cells from aged wild type mice, which also upregulate IgH transcripts [14], previously
regarded sterile, also upregulate cell surface IgG protein (Figure 7I). However in contrast to
arthritic KSL cells, IgG2b, not IgG1, is the isotype upregulated (Figure 7I). Therefore, arthritic
uncommitted progenitors specifically upregulate IgG1 at the mRNA and protein levels.
These result raise a number of questions. What is the mechanism of IgG1 synthesis in
arthritic primitive progenitors? Is there still a germline configuration at the IgG locus in these cells
or does VDJ recombination and class switching occur? Physiologically IgG1 protein cannot be
synthesized until after class switch recombination in activated B cells. This results in reduced Cµ
and Cγ germline transcripts (GLTs) and increased Cγ post switch transcripts (PST). However we
found that Cµ GLT were still very prominent in arthritic KSL cells as in controls while Cγ1 PSTs
was still very low (Figure 7J). Therefore it is possible that some other mechanism, such as
alternative processing of IgH transcripts [18] occurs in arthritic primitive progenitors.
Another question based on these findings is the significance of IgG upregulation of
primitive progenitors in arthritis and aging. It is interesting to note that the predominant IgG
isotype produced in KRNxG7 arthritis is also IgG1 [17-20]. It is not clear though if this increased
surface IgG on arthritic KSL cells is capable of recognizing arthritogenic epitopes of GPI, but GPI
transcripts are curiously also upregulated in arthritic KSL cells as well (Figure 2D).
In summary KSL cells from arthritic mice have upregulated P selectin and IgG
reminiscent of primitive progenitors in normal aging, another epigenetic state characterized by
myeloid skewing.
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Figure 1. KSL sorting and validation
A. Scheme for sorting KSL cells and checking purity of sort. Residual Lin+ cells after lineage
depletion (more prominent in arthritic samples) were efficiently excluded during FAC sorting.
hi

Besides reduced Kit Sca1-Lin- MEPs (Figure 1C and unpublished), Kit versus Sca FACS plot
of arthritic mice is similar to that of control mice, and is devoid of the overt Sca1 shift present
in some models of inflammation (See Figure S2B).
B. Methylcellulose colony replating of sorted BM GMP and KSL cells. “GM restricted” medium
contains recombinant KitL, Interleukin (IL)-3 and -6 without erythropoietin (EPO). “Erythroid
restricted” medium is serum free and contains EPO. (See Methods for source of media).
C. GM restricted methylcellulose plates (day 7-8) containing recombinant SCF, IL-3 and IL-6
depicting macroscopic KSL derived colonies from arthritic or control mice, visible as specks.
GMP derived colonies are only visible under a microscope.
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D. Dendrogram comparing arthritic KSL enriched expression profile (“hematopoietic progenitor
1c; red color) and control KSL enriched expression profile (“hematopoietic progenitor 1a &
1b”) to each other and to profiles of stem cells (green) and mature cells (blue) from previous
studies (See Table S2). Mature Lin+ expression was used as a baseline for determining KSL
enriched genes. Profile of genes enriched in arthritic KSL cells relative to control KSL cells is
represented by “arthritic KSL enriched”.
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Figure 2. Upregulated myeloid genes and cytokine receptors in arthritic KSL cells based
on microarray analysis
A. Functional annotation terms enriched in genes downregulated in arthritic KSL cells based on
DAVID Bioinformatics analysis (Reference #5, Huang da et al, 2009). Only terms with at least
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3 genes represented in the downregulated gene list with p<0.05 were used in the analysis.
Top 10 most statistically significant terms (based on “p value”). Orange arrows highlight GO
terms “External Side of Plasma Membrane”, “Cell Surface” and “Transmembrane protein”.
B. Microarray based heat map depicting cytokine receptors upregulated in arthritic KSL relative
to both B6xG7 (control 1a) and KRN (control 1b) KSL populations.
C. Functional annotation terms enriched in genes upregulated in arthritic KSL cells based on
DAVID Bioinformatics analysis (Reference #5, Huang da et al, 2009). Only terms with at least
3 genes represented in the upregulated gene list with p<0.05 were used in the analysis. Top
10 most enriched terms (based on “fold enrichment”). Orange arrows highlight GO terms
“PIRSF005879:CCAAT/enhancer-binding protein”, PIRSF005879:CCAAT/enhancer-binding
and CCAAT/enhancer-binding.
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D. Microarray based heat map depicting selected genes upregulated in arthritic (KRNxG7) KSL
cells relative to both B6xG7 (control 1a) and KRN (control 1b) KSL populations.
E. Microarray based heat map depicting selected genes downregulated in arthritic (KRNxG7)
KSL cells relative to both B6xG7 (control 1a) and KRN (control 1b) KSL populations.
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Figure 3. Validation of upregulated myeloid genes and downregulated erythroid genes in
KRNxG7 arthritic KSL cells obtained from microarray analysis
A. QRT-PCR analysis of FcγRIIb and FcγRIII transcripts in sorted KSL and GMPs. Internal
control for subsequent qRT-PCR analysis
B. QRT-PCR analysis of cyclin dependent kinase inhibitor, p21 in sorted arthritic (KRNxG7) and
control (B6xG7) KSL cells. Internal control for subsequent qRT-PCR analysis
C. QRT-PCR validation of selected genes based on microarray. GAPDH normalized expression
using 3 independently sorted KSL RNA different from pools used for microarray. Genes in red
box are part of a “myeloid inflammatory signature” based on consistent upregulation in KSL
cells from KRNxG7 arthritis and serum transfer arthritis models (See Figure 4 & 5)
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D. Left: FcγRIII/IIb protein expression on KSL cells and GMP determined by FACS. Histograms
from 2 arthritic mice (KRNxG7) and 2 control mice (KRN) are shown.
Right: Median fluorescence intensity (MFI) of Anti-FcγRIII/IIb-PE signal on gated KSL cells
and GMP as a surrogate quantification of FcγRIII/IIb surface protein level. Representative of
at least 2 experiments with at least 3 arthritic and control mice per experimental set up.
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Figure 4. Myeloid Priming can be induced in naïve KSL cells by arthritogenic serum
transfer
A. Analysis of bone marrow Mac1+Gr1+ frequencies in serum injected (arthritis) and PBS
injected (control) B6 mice 7 days post injection. Mean and standard deviation for N=3 mice
each is shown.
B. Analysis of bone marrow progenitor frequencies in serum injected (arthritis) and PBS injected
(control) B6 mice 7 days post injection. Mean and standard deviation for N=3 mice each is
shown.
C. Quantitative RT-PCR of selected genes in KSL cells from serum transfer arthritic mice and
control PBS injected mice. “Myeloid inflammatory signature genes” are highlighted with a red
box (See Figure 3 & 5)
D. Analysis of hematopoietic frequencies in 3 wk old KRNxG7 (prior to detectable joint swelling)
and control mice. Modest Mac+Gr1lo increase is similar to serum transfer arthritis.
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Figure 5. Upregulation of myeloid inflammatory signature genes exists at the most
primitive HSC subset of KSL cells
A. Quantitative RT-PCR of transcription factors in arthritic and control HSCs (CD150+CD48CD34-KSL IL7Rα-). Mean and standard deviation of GAPDH normalized expression is
shown.
B. Quantitative RT-PCR of “myeloid inflammatory signature genes” (See Figure 3 & 4) in arthritic
and control HSCs (CD150+CD48-CD34-KSL IL7Rα-).
C. Table comparing fold increase in expression of “myeloid inflammatory signature genes” in
arthritic KSL cells and HSCs relative to controls (based on Figures 3C, 4C & 5B).
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Figure 6. Protein expression of cytokine receptors on KSL cells
Protein expression of cytokine receptors on KSL cells from KRNxG7 arthritic mice (black
histograms) and KRN control mice (blue histograms) were determined by flow cytometry. Red
histogram represents isotype control staining. Besides IL-21R, the remaining cytokine receptors
are detected on KSL cells. However no difference can be delineated between KRNxG7 and KRN
KSL cells. Similar results were obtained using G7 as control.
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Figure 7. Upregulatin of P selectin and IgG1 protein in arthritic KSL cells
A. Heat map illustrating upregulated P selectin and immunoglobulin heavy chain transcripts in
arthritic (KRNxG7) KSL cells relative to B6xG7 (Control 1a) and KRN (Control 1b) controls.
The dChip annotations given does not accurately reflect the gene identified by these
probesets. See Figures 7C & 7D.
B. Flow cytometry showing P-selectin protein expression on arthritic and control KSL cells. Each
histogram is from a single mouse. Histograms from 4 arthritic mice (black) and 4 control mice
(orange) are shown. Rightward shift of arthritic KSL cells indicate increased cell surface Pselectin protein expression and corroborates upregulation of P selectin transcript in arthrtic
KSL cells based on microarray experiment.
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C. Target sequences for all immunoglobulin heavy chain affymetrix microarray probes
upregulated in KRNxG7 KSL cells from Figure 7A.
D. Genomic sequence of the mouse IgG1 constant region (Cγ1) locus extracted from Ensemble.
There are 4 exons (Ex) highlighted by light brown background shading and Ex1,2,3,4
annotations. Target sequences for all immunoglobulin heavy chain affymetrix microarray
probes upregulated in KRNxG7 KSL cells (See Figure 7C) are located in exon 4. Sequence
letters are colored to match the colors of target sequences shown in Figure 7C. Other
sequence letters within exons are in dark brown font. Non coding regions (e.g. introns) are in
black font Reverse primer for GLT/PST analysis used in Figure 7J below is underlined and
st

lies within the 1 exon.
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E. IgG1 constant region cDNA showing sequences corresponding to primers used for qRT-PCR
validation. The start of exons 2,3,4 are shown in red. QRT-PCR primer sequences are
shown in bold. In primer set 1, forward and reverse primers are in exon 1. In primer set 2,
forward primer is in exon 3, reverse primer is in exon 4.
F. QRT-PCR of IgG1 constant region (Cγ1) expression by KSL cells and HSCs (CD150+CD48CD34-KSL). KSL cells and HSCs were sorted from pools of mice independent from those
used for microarray experiment. Each dot represents expression from an individual mouse or
pool of mice.
G. Flow cytometry of cell surface immunoglobulin (IgG) protein on KSL cells. IgG – Total IgG
using rat polyclonal antibody. A goat polyclonal antibody to mouse IgG also gave the same
result (Not shown). IgG1, IgG2b and IgG3 isotypes are detected using specific rat
monoclonal antibodies. All staining was performed in the presence of FcγR blocking antibody
to prevent non-specific interaction between cell surface IgG and fluorophore conjugated antiIgG antibodies. Isotype control is shown in green.
H. Surface immunoglobulin expression on KSL cells from young B6xG7 mice induced to develop
arthritis by serum transfer and control B6xG7 mice injected with PBS. Ig heavy chain
molecules γ1, γ2b, γ3 and Ig light chain molecule κ were assayed.
I.

Surface IgG expression of KSL cells from old (22 months) B6xG7 mice (Black Histograms)
compared with young B6xG7 mice (Orange Histograms). Same antibodies used in Figure 7G
were used.

J.

QRT-PCR analysis of germline and post switch transcripts (GLT and PST respectively) of
immunoglobulin heavy chain genes (µ, γ1, γ2b, γ3) in sorted arthritic KSL cells (black) and
KSL cells from two control strains (B6xG7 – red, KRN – blue).
Insert: PST abundance normalized to GLT abundance of the γ heavy chain isotypes.
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CHAPTER 4
CELL INTRINSIC FUNCTIONAL DIFFERENCES BETWEEN ARTHRITIC AND CONTROL
PRIMITIVE PROGENITORS

Most of the contents of this chapter has been published in Oduro KAJ et al, 2012. Blood
120:2203
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OVERVIEW
Our gene expression analysis (Chapter 3) suggested that primitive progenitors including
HSCs were primed towards myeloid development by virtue of upregulated myeloid specific
transcripts. KSL cells from arthritic mice also shared certain unique similarities with primitive
progenitors from aged wild type mice specifically the upregulation cell surface P selectin and IgG.
These KSL changes correlated with increased myeloid output in arthritic mice (Chapter 2).
However, the magnitude of gene expression changes in arthritic KSL cells for most genes was
modest. Increased cell cycling, which is typically associated with activated progenitors, does not
occur in arthritic primitive progenitors either (Chapter 2). Therefore the question still remains
whether the gene expression changes in arthritic KSL cells have any functional significance with
respect to KSL properties.
Therefore in this chapter, we sorted KSL cells from arthritic and control mice and
prospectively tested their lineage potential in vitro and in vivo. With the help of competitive and
non-competitive, instructive and permissive assay conditions, we define concepts of capacity and
propensity in understanding progenitors that on the one hand are still “primitive” but on the other
hand are “lineage primed”. We demonstrate functionally that arthritic primitive progenitors indeed
have superior myeloid generation potential and are thus myeloid primed.

IN VITRO ASSESSMENT OF MYELOID PRIMING
Arthritic KSL cells have increased myeloid potential in vitro
As mentioned earlier, in vitro colony formation in semi-solid medium replete with
differentiation promoting cytokines was not significantly different between arthritic and control
KSL cells while both populations had superior activity to GMPs (Chapter 3; Figure 1b). However,
recent studies have shown that myelopoietic cytokines in culture act instructively rather than
providing a permissive environment for hematopoietic differentiation [1-3]. Therefore while they
allow evaluation of differentiation capacity, as utilized earlier for clarifying KSL versus GMP
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properties (Chapter 3), they are inadequate in evaluating the relative propensities of arthritic and
control KSL cells in generating particular lineages.
We therefore established a “competitive in vitro culture system” in which equal numbers
of arthritic and control KSL cells were mixed in liquid culture without differentiation cytokines but
with KitL and Flt3L to promote viability [4-6] (Figure 1A). Arthritic and control KSL cells were
obtained from mice with different CD45 (Ly5) alleles to allow tracking of their relative cell output.
Under this permissive condition there was about up to a 13-fold expansion of cells after 3-4 days
of culture although this was variable. Twenty percent of these cells still remained Kit+Linindicating they were still immature (Data Not Shown). About 40-60% of all cells generated were
Mac1/Gr1+ but negative for other lineage markers (B220 for B cells, CD3 and TCRβ for T cells,
and Ter119 for erythrocytes) and therefore were myeloid cells (Figure 1B). Thirty percent of these
myeloid cells expressed Kit indicating that the myeloid population consisted of a mixture of cells
with different levels of maturity (Data Not Shown). Consistent with a greater myeloid propensity of
arthritic KSL cells, myeloid cells (Mac1/Gr1+B220-CD3-TCRβ-Ter119-) derived from arthritic KSL
cells was about 3-fold more than those derived from control KSL cells (Figure 1B & 1C).
While the inflammatory phenomenon in arthritic mice is characterized by increased
neutrophils, the bone destruction that occurs at the joint is mediated by osteoclasts, which are
also of myeloid lineage. The bone marrow Mac1+Gr1lo population that was increased in arthritic
mice (Chapter 2: Figure 6A) has previously been reported to also contain osteoclast precursors
[7]. Furthermore our KSL gene expression analysis revealed upregulation in arthritic KSL cells of
several genes previously implicated in osteoclastogenesis including Chi3l3 [8, 9], S100a8 [10],
Ccr2 [11], Ccl9 [12-14] and Sh3bp2 [15]. On the other hand IFNγ, which suppresses
osteoclastogenesis [16], and several IFNγ regulated genes were reduced in arthritic KSL cells
while Adar1, which is a negative regulator of interferon signaling [17] was increased (Chapter 3:
Figure 2E and Not Shown). Therefore, we also tested if arthritic KSL cells had a specific increase
in osteoclastogenic potential as a part of the overall increase in myeloid generation propensity.
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Osteoclasts are multinucleate cells resulting from cell fusion that are identified by a histochemical
stain. This precludes the use of competitive assays to compare osteoclastogenic potential.
However, previous attempts to generate osteoclast in vitro from early progenitors found that
osteoclast generation occurred only after prior activation of the progenitors with IL-3 [18].
Therefore we surmised that an increased osteoclastogenic potential of arthritic KSL cells would
be detectable even in non-competitive assays.
We prospectively sorted KSL cells from arthritic and control mice and cultured them in
vitro in osteoclastogenic conditions – that is in the presence of M-CSF and RANKL – without any
prior activation. Consistent with previous attempts, KSL cells from control mice largely failed to
develop osteoclasts in vitro while KSL cells from arthritic mice were able to generate osteoclasts
(TRAP+ multinucleate cells) (Figure 1D). Arthritic KSL containing wells displayed osteoclast
potential ~80% (15/19) of the time. On the rare occasion that control KSL cells formed
osteoclasts, these cells were invariably smaller and/or fewer than those formed from arthritic KSL
cells (Figure 1D and not shown). This property was arthritis dependent because KSL cells sorted
from 2 week old KRNxG7 mice, which is prior to onset of visible disease (joint swelling) also failed
to develop osteoclasts (data not shown). Only 2000 KSL cells from arthritic mice was sufficient to
form in vitro osteoclasts although the osteoclasts were not generated as robustly as could be
generated from GMP committed progenitors (Figure 1D). Taken together, arthritic KSL cells have
increased in vitro myeloid generation propensity that is also reflected in an increased in vitro
osteoclastogenic potential.

Arthritic KSL cells have diminished lymphopoietic propensity in vitro
It still remained possible that arthritic KSL cells performed better in these assays because
of some non-specific reason such as better viability in vitro. For example from microarray analysis
(Chapter 3: Figure 2D) arthritic KSL cells had marked upregulation of the stress combative
inducible heat shock proteins Hspa1a and Hspa1b, which may protect arthritic KSL cells during in
vitro culture. Therefore we examined lymphopoiesis of KSL cells in vitro. KSL cells from either
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KRNxG7 arthritic or control mice cultured on OP9 stromal cells with B lymphoid promoting
cytokines KitL, Flt3L and IL-7 thrived and expanded 100-1000 fold relative to input KSL cell
number after about a week of culture (Figure 2A). About 50% of these cells produced were
B220+ cells, which were also Gr1- (Figure 2B and Data Not Shown). These B220+ cells
segregated into 2 main populations: B220+CD11c-Mac1- B cell precursors and
B220+CD11c+NK1.1- putative lymphoid dendritic cell precursors [4, 19] (Figure 2C). Under these
non-competitive culture conditions, KSL cells from arthritic or control mice generated similar cell
output, similar frequency of total B220+ cells and similar frequency of the B220+ subsets
indicating they had similar lymphopoietic capacity. By comparison, GMP cells, which lack
lymphopoietic capacity failed to appreciably expand under these conditions (Figure 2A); GMP
seeded wells accumulated debris, and most cells were dead as determined by eosin viability dye
staining (not shown).
Next, we compared lymphoid generation propensity of arthritic and control KSL cells in
competitive in vitro cultures under the same conditions – on OP9 cells in the presence of KitL,
Flt3L and IL7. B220+Gr1- cells were preferentially (about 2 fold) derived from control KSL cells
(Figure 2D). B220+CD11c- B cell precursors and especially B220+CD11c+ putative lymphoid
dendritic cells precursors were both preferentially derived from control KSL cells (Figure 2D).
Therefore arthritic KSL cells have diminished lymphopoietic propensity compared with control
KSL cells. This suggests that the increased myeloid output of arthritic KSL cells in vitro that we
previously demonstrated (Figure 1) is specific and unlikely due to non-specific factors like
increased survival. While arthritic KSL cells still have the capacity for differentiation into other
lineages such as lymphoid lineages their propensity is compromised presumably resulting from
their myeloid primed state.
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Increased in vitro myeloid potential and decreased lymphoid potential is inducible in naïve
mice by arthritogenic serum transfer
We showed earlier (Chapter 3) that upregulation of “myeloid inflammatory signature”
genes defined in KRNxG7 arthritic KSL could be triggered in KSL cells in naïve mice induced to
develop arthritis by arthritogenic serum transfer. This demonstrated the disease dependence of
the gene expression changes. To determine if the increased myeloid propensity and decreased
lymphoid propensity of KSL cells from KRNxG7 mice was indeed arthritis dependent, we induced
serum transfer arthritis in B6xG7 and injected control mice with PBS. KSL cells from serum
injected and PBS injected mice were then sorted and cultured competitively in both stromal cell
free and OP9 culture media to test myeloid and lymphoid propensity respectively (Figure 3A). In
all cases, KSL cells from serum transferred mice contributed more to Mac1/Gr1+ myeloid output
(Figure 3B) while the very same KSL cells contributed less to B220+CD11c-Mac1- lymphoid
output (Figure 3C). This corroborates the results with KRNxG7 arthritic KSL cells and shows that
the increased myeloid and decreased lymphoid potential in vitro are arthritis dependent.

IN VIVO ASSESSMENT OF MYELOID PRIMING
Arthritic KSL cells have increased myeloid potential in vivo
To determine whether myeloid priming of arthritic KSL cells could also be manifested in
an in vivo setting we performed competitive transplantation experiments. We initially generated
mice that were histocompatible to both KRNxG7 arthritic mice and B6xG7 control mice but were
Ly5 congenic with respect to both prospective donors to serve as transplantation recipients.
Equal numbers of sorted KSL cells from arthritic and control mice with different Ly5 alleles were
then transplanted into lethally irradiated young (2-3 months old) recipients (Figure 4A). This
experimental set up allowed us to differentiate cells derived from arthritic KSL donor, control KSL
donor and residual cells from the recipient based on Ly5 staining. Myeloid and B lymphoid cell
output were tracked using Mac1 and B220 respectively. Co-staining with Gr1 and CD19
respectively confirmed the myeloid and B lymphoid status of cells analyzed (Not shown).
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Six days after transplantation, we found that myeloid cells were preferentially derived
from arthritic KSL cells (about 5 fold) (Figure 4B & 4C). Sixteen days post transplantation,
myeloid cells were still preferentially derived from arthritic KSL cells although less so (about 2
fold) (Figure 4C). However at 5 weeks and beyond, myeloid cells were equally derived from
arthritic and control KSL cells. On the contrary, B lymphoid contribution was greater from control
mice with the difference disappearing with increased time post transplantation. Therefore arthritic
KSL cells generate myeloid cells with relatively faster kinetics and lymphoid cells with slower
kinetics compared with control KSL cells. In some experiments, both myeloid and lymphoid
engraftment from arthritic KSL cells were lower than from control KSL cells (Data Not Shown).
However even in this situation, myeloid engraftment from arthritic KSL cells was superior to
lymphoid engraftment.
The similar contribution to myeloid and lymphoid cells from arthritic and control KSL cells
beyond the very early weeks post transplantation was consistent with our previous transplantation
experiments using whole bone marrow instead of sorted KSL cells [20]. Furthermore, the
restoration of a balanced myeloid and lymphoid output from arthritic KSL cells corroborated our in
vitro findings that arthritic KSL and control KSL cells have similar differentiation capacity even
though arthritic KSL cells have a skewed differentiation propensity towards myeloid development.

Myeloid priming occurs in the most immature HSC fraction of arthritic KSL cells
Although our data so far suggests myeloid priming in the arthritic KSL population, it is
unclear if the most immature self-renewing HSCs are also affected. Unequivocal detection of
HSC contribution in in vivo transplantation requires assessment several weeks (at least 16 weeks
and more convincingly 6 months) post transplantation [21]. At earlier time points, contribution by
this so called long term reconstituting HSCs (LT-HSCs) is minimal and is confounded by
contribution by less primitive HSPPCs with limited or absent self-renewal. Therefore the detection
of preferential myeloid contribution of arthritic KSL cells only at early time points (<5 weeks;
Figure 4C) suggested that myeloid priming or arthritic KSL cells might not exist in the self-
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renewing LT-HSC fraction. Alternatively it was possible that LT-HSCs are indeed affected but in
an environment dependent manner. Functional outcomes due to cell autonomous genetic
modifications are easily detected long after transplantation because genetic modifications are
stable. On the other hand, since epigenetic changes including environmentally induced
perturbations are reversible, their functional outcome would only be detectable in the long term if
the change is inherently stable or if the recipient environment maintains the change. We surmised
that the environment of young B6xG7 recipients (Figure 4) could erase/reverse myeloid priming of
arthritic LT-HSCs and was hence unsuitable to test myeloid priming of arthritic LT-HSCs.
Therefore we considered using old mice as recipients. Similar to arthritic mice, aged wild
type mice have an increase in myeloid cells and an increased myeloid potential of HSCs [22].
This phenomenon is at least in part environmental driven because transplanted HSC enriched
population from young mice generate significantly more myeloid cells and less B lymphoid cells in
the old recipient relative to young recipient [22]. We reasoned that since aged environment
supports myeloid development it would be less likely to reverse myeloid priming of transplanted
cells. We competitively transplanted equal numbers of arthritic (KRNxG7) and control (B6xG7)
KSL cells from young mice (2-3 months old) into old (20 months old) B6xG7 recipients (Figure
5A). Donors and recipients were congenic with respect to Ly5 allowing us to distinguish KRNxG7
donor, B6xG7 donor and B6xG7 recipient derived cells.
Eight weeks after transplantation, myeloid cell frequency in peripheral blood was around
40%, higher than myeloid cell frequency of young recipients, and indicating that environmental
effects of the aged recipient is preserved despite lethal irradiation and transplantation (Figure 5B).
At this time point (8 weeks) myeloid (Mac1+Gr1hi) cells in the old recipient mice were
preferentially derived from arthritic KSL cells (1.7 fold) while in contrast B lymphoid (B220+) cells
were equally derived from donor arthritic and control KSL cells (Figure 5C & 5D). In fact relative
contribution to Mac1+Gr1hi myeloid cells by arthritic KSL cells was still greater than relative
contribution to B220+ cells at 16 weeks and 6 months post transplantation (Figure 5D), time
points reconstituted solely by LT-HSCs [21]. Therefore, LT-HSCs within arthritic KSL cell
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population have greater in vivo myeloid potential than control LT-HSCs but is undetectable when
young recipients are used.
Primitive progenitors from arthritic mice also engraft old recipients better than control
cells as evinced by bone marrow KSL chimerism analysis 6 months post transplant (Figure 5E).
This might also explain the increase in arthritic KSL derived lymphoid and myeloid cells at 16wks
and 6 months post transplantation (Figure 5D). In fact, similar results are obtained when young
recipients which showed a balanced lineage output 9 weeks post transplantation (Figure 4C) are
analyzed several (7-10) months after transplantation when these recipients are no longer
chronologically “young” (Figure 5F & 5G). 10 months after transplantation contribution of arthritic
KSL cells to both lymphoid and myeloid lineages (Figure 5F) as well as to bone marrow KSL cells
is increased (Figure 5G).
Lastly, we transplanted KSL cells from old donors into young recipients using KSL cells
from young B6xG7 donors as competitors (Figure 6A). 20 month old KRNxG7 arthritic KSL cells
or B6xG7 KSL cells reconstituted 50-70% of myeloid cells but only 15-30% of lymphoid cells
consistent with the known lineage skewing of primitive progenitors with age [22]. At 16 weeks
post transplantation when HSC output can be assessed, we found that KSL cells from old (~20
month old) KRNxG7 arthritic mice performed better in myeloid reconstitution than in lymphoid
reconstitution (Figure 6B). Myeloid reconstitution from old KRNxG7 arthritic mice was not
significantly different from old B6xG7 myeloid reconstitution (Figure 6B). However, lymphoid
reconstitution from old KRNxG7 arthritic mice was about half the lymphoid reconstitution from old
B6xG7 mice (Figure 6B). We did not see these effects when we used 5 month old donors instead
of 20 month old donors (Figure 6C). Therefore increased duration of arthritis – 20 month instead
of 2 months (Figure 4C) or 5 months (Figure 6C) – increases the epigenetic stability of the
myeloid primed state in arthritic KSL cells permitting its detection in young recipient mice.
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MOLECULAR MECHANISM OF MYELOID PRIMING
Possible Roles for TLR4 and S100 proteins
The molecular mechanism by which myeloid priming occurs in arthritic primitive
progenitors is unclear at the moment. Transcription factors Stat3 and C/EBPβ and the IL6 coreceptor IL-6st (gp130), which play crucial roles in non-steady state granulopoiesis [23-25], are all
upregulated in arthritic KSL cells. However it remains to be established whether they act at the
KSL level or in downstream GMPs or myeloid precursors. On the other hand, TLR4 stimulation
using LPS drives proliferation and differentiation of KSL cells into myeloid cells [4, 26]. A number
of studies have highlighted the importance of TLR4 in various arthritis models [27-34]. In the
K/BxN arthritis model in particular, it has been shown that while TLR4 mutant mice developed
arthritis upon K/BxN arthritogenic serum transfer, the arthritis was short lived compared with
arthritis induced in TLR4 sufficient mice [27]. Furthermore, the TLR4 ligand, LPS exacerbates
arthritis in TLR4 sufficient animals while permitting arthritis development in IL-1R knockout mice,
which are otherwise resistant to serum transfer arthritis [27, 35].
Therefore we first examined expression of TLR4 on the surface of KSL cells. TLR4 is
detectable on KSL cells as previously reported [4] but is very low (Figure 7A). Interestingly we
found that the TLR4 signal was diminished on the surface of arthritic KSL cells while intracellular
TLR4 was abundant and similar between arthritic and control KSL cells (Figure 7B). Even though
the KRNxG7 model is free of LPS, this result was reminiscent of the effect of LPS stimulation,
which also decreases cell surface TLR4 signal by receptor internalization or altered conformation
[36, 37]. We therefore predicted that arthritic KSL cells might exhibit diminished responsiveness
to de novo LPS stimulation. We sorted KSL cells from KRNxG7 arthritic mice and CD45 congenic
B6xG7 mice and set up in vitro stromal cell free competitive culture in the presence of different
concentrations of LPS (Figure 7C). We found that while arthritic KSL cells generated more
myeloid cells than control KSL cells did in the absence of LPS, consistent with the myeloid primed
state of arthritic KSL, the myeloid contribution from arthritic KSL cells decreased with increasing
LPS dose (Figure 7D). This effect was recapitulated in in vitro competitive stromal cell free culture
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using KSL cells from B6xG7 serum transferred arthritic mice versus B6xG7 PBS transferred
control mice (Figure 7E). Therefore arthritis renders KSL cells more refractory to LPS stimulation
by reducing responsive TLR4 on the cell surface.
This raises two questions. First, is signaling through TLR4 required for the myeloid
primed state of arthritic primitive progenitors such that signaling by some endogenous molecule
drives the myeloid primed state and downregulates surface TLR4 in the process? A candidate
molecule in this respect is S100a8 which we found to be consistently and markedly increased in
arthritic KSL cells and more primitive HSCs (CD150+CD48-CD34-KSL; See Chapter 3). Recently,
it was reported that S100a8 is capable of acting as an endogenous TLR4 ligand [38]. S100a8
protein typically heterodimerizes with the related protein S100a9, which probably stabilizes the
S100a8 protein since S100a8 protein is undetectable in S100a9-/- mice despite the presence of
S100a8 mRNA [39]. S100a9 was also increased in arthritic KSL cells and HSCs. S100a8 and
S100a9 are in fact the most abundant protein in the cytoplasm of mature neutrophils and have
been implicated in arthritis and other inflammatory states [40, 41]. It has also been reported that
transgenic overexpression of S100a9 skews development of myeloid derived suppressor cells
over dendritic cells and macrophages in cancer [42] indicating that S100 proteins can affect
differentiation outcome. We are currently conducting experiments to test the hypothesis that
endogenous S100a8/S100a9 produced by arthritic HSCs promote the myeloid propensity of
these cells by autocrine stimulation of TLR4 pathways or other means.
The second possibility is that cell surface TLR4 signaling is a negative regulator of the
myeloid primed state such that its downregulation on the cell surface promotes myeloid priming of
primitive progenitors in arthritic mice? Endogenous TLR4 ligands like S100a8 could still be
involved in this mechanism but in this case, TLR4 downregulation not necessarily TLR4 signaling
is what drives myeloid priming.
To determine the role of TLR4 in myeloid priming of primitive progenitors in arthritis we
would use TLR4 -/- mice. The most obvious experiment will be serum arthritis induction in TLR4-/versus TLR4+/+ mice followed by KSL sorting and functional assessment. However since the
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course of arthritis disease is different in these two strains we would be unable to distinguishably
attribute a reduced myeloid potential in KSL cells from TLR4-/- mice to disease severity (KSL
TLR4 independent) or to a direct TLR4 dependent effect on KSL cells.
Therefore we have established an experimental scheme which would be widely
applicable in teasing out the molecular mechanisms of KSL myeloid priming in vivo (Figure 8).
This involves generating bone marrow chimeric mice from the mutant mice (e.g. TLR4-/-) and
CD45 congenic wild type mice. This is followed by serum arthritis induction of the chimeric mice
after engraftment and steady state is achieved (typically 6-8 weeks). In most cases mice will still
be susceptible to the disease because of the presence of wild type cells in the chimeric mice.
More importantly, both wild type and mutant KSL cells would be exposed to the same disease
environment. Mutant and wild type KSL cells can then be sorted based on different CD45 allele
expression and myeloid potential assessed prospectively.
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Figure 1. Arthritic KSL cells have increased in vitro myeloid potential
A. Experimental scheme for in vitro competitive culture of arthritic and control KSL cells. Arthritic
and control mice have different CD45 (Ly5) alleles. 5000 each of arthritic and control KSL
cells were mixed in the same well of a 24 well plate with survival cytokines, KitL+Flt3L and
media containing 10% serum.
B. Top: FACS plot depicting myeloid differentiation of KSL cells in vitro after 3.5 days of culture.
Myeloid cells (red gate) are Mac1+ and/or Gr1+ and negative for B cell (B220), T cell (CD3,
TCRβ) and Erythrocyte (Ter119) markers. About 40-60% of cells were present in this gate.
Bottom: FACS plot depicting chimerism analysis to determine arthritic KSL derived (Ly5.2+)
and control KSL derived (Ly5.1+) myeloid cells.
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C. Summary of in vitro competitive culture results. Each bar represents outcome of KSL cells
from 1 independent arthritic mouse competed with control KSL cells. In 5/6 cases arthritic
KSL cells (black) contributed greater to myeloid cell output.
D. TRAP stained wells at least 6 days after culturing sorted KSL and GMPs with M-CSF and
RANKL to promote osteoclastogenesis. Low magnification camera images and high
magnification microscopy images of wells are shown. TRAP+ cells are pink/purple. The few
TRAP+ cells in wells seeded with control KSL cells are not multinucleate unlike arthritic KSL
and GMP derived cells.
***p<0.001
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Figure 2. Arthritic KSL cells have reduced in vitro lymphoid potential
A. Cell output 6-7 days after growing 3000 sorted BM KSL cells or GMPs from arthritic
(KRNxG7) and control (G7) mice on irradiated OP9 feeder cells in the presence of KitL, Flt3L
and IL-7 to promote B cell differentiation.
B. Frequency of B220+Gr1- after culturing arthritic (KRNxG7) and control (G7) KSL cells on
irradiated OP9 cells and media containing 10% serum, KitL, Flt3L, IL-7 to promote lymphoid
cell formation. “Non competitive” culture means KSL cells from arthritic and control mice were
seeded into different wells and were not mixed. Although G7 control mice are used here,
similar results are obtained when other control strains are used (Data not shown).
C. Schematic of detailed FACS analysis of B220+ cells from D5-7 OP9 culture of KSL cells and
frequency of B220+ subsets. B220+ consist of a CD11c+ subset that are predominantly
Mac1+ but Gr1- that are also NK1.1- (putative dendritic cell precursors) and CD11c- subset
that are predominantly Mac1-Gr1- (putative early B cell precursors). NK1.1+ cells (NK lineage
cells), subsets of which express B220, are not generated.
D. Relative contribution of arthritic (KRNxG7) and control (KRN) KSL cells to total B220+Gr1cells, B220+CD11c+ and B220+CD11c-Mac1- cells when KSL cells are seeded in the same
wells and grown competitively (1:1) on irradiated OP9 cells with KItL, Flt3L and IL-7. Control
and arthritic KSL cells were distinguished by CD45 (Ly5) allele expression. A different cohort
of mice (N=3 each time) was used for the total B220+ analysis and the B220+ subset
analysis.
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Figure 3. Increased myeloid and decreased lymphoid potential can be induced in KSL cells
by arthritogenic serum transfer into naïve mice
A. Experimental scheme arthritis induction in naïve mice (B6xG7) by injection of serum. Control
mice were injected with PBS. Serum injection was administered on Day 0 (D0) and D2 and
KSL cells sorted for competitive in vitro stromal cell free and OP9 culture with indicated
cytokines on D7.
B. Relative contribution of arthritic (serum injected) and control (PBS injected) KSL cells to
Mac1/Gr1+ cells generated in in vitro stromal cell free culture. Each bar represents outcome
of KSL cells from 1 independent arthritic mouse competed with control KSL cells.
C. Relative contribution of arthritic (serum injected) and control (PBS injected) KSL cells to
B220+CD11c-Mac1- B cells generated in in vitro culture on OP9 cells with lymphopoietic
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cytokines. Each bar represents outcome of KSL cells from 1 independent arthritic mouse
competed with control KSL cells.

Figure 4. Arthritic KSL cells have increased in vivo myeloid potential although it is not
sustained in young recipients
A. Experimental scheme for competitive in vivo transplantation. Donors and recipients have
distinct Ly5 alleles.
B. FACS plot depicting analysis of Ly5 chimerism of bone marrow Mac1+ cells in recipient mice
6 days after transplantation.
C. Quantification of arthritic and control KSL contribution to Mac1+ and B220+ cells in bone
marrow (BM) and peripheral blood (PB) based on Ly5 chimerism.
*p<0.05**p<0.01***p<0.001 relative to control KSL derived cells
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Figure 5. Long term In vivo myeloid potential of most primitive HSC subset of arthritic KSL
cells is revealed by old recipient transplantation
A. Experimental scheme for transplantation into old (~20 month old) B6xG7 recipients. Note that
CD45 alleles of B6xG7 donor, KRNxG7 donor and B6xG7 recipient mice are slightly different
from what was used for the young recipient experiment.
B. Peripheral blood (PB) frequency of myeloid (Mac1+), B cells (B220+) and T cells (CD3+) after
competitive transplantation of arthritic and control KSL cells. Extrapolation (orange hatched
line) indicates myeloid frequency about 2 months post transplantation.
Left: Young (2-3 month old) recipients (See Figure 4). At early time points Mac1+ cells
hi

lo

express Gr1 homogenously and Gr1 versus Gr1 cells cannot be resolved (Not Depicted).
PB Myeloid frequency 2 months post transplantation is <20%.
Right: Old (20 month old) recipients (See Figure 5A). PB Mac1+ frequency 2 months post
transplantation is about 40%. CD3 frequency was not determined at the 26 wk time point.
C. Representative FACS plots showing gating scheme for analysis of myeloid cells
(Mac1+Gr1hi), B cells (B220+; also CD3-) and T cells (CD3+; also B220-) in peripheral blood
of recipient mice 8 weeks after transplantation. Gated cells are further analyzed for CD45.1
(Ly5.1) versus CD45.2 (Ly5.2) to determine arthritic donor derived cells (Ly5.1+) versus
control donor derived cells (Ly5.1+) versus recipient derived cells (Ly5.1+Ly5.2+).
D. PB chimerism 8 weeks (wks), 16wks and 26wks (6 months) post transplantation using old
recipients gated on Mac1+Gr1hi myeloid cells or B220+ cells. Percentage change of arthritic
KSL derived Mac1+Grhi or B220+ cells relative to control KSL derived cells is indicated in
blue.
E. BM KSL chimerism 26wks post transplantation using old recipients
F. PB chimerism 7 months and 10 months post transplantation using young (2-3 month old)
recipients gated on Mac1+Gr1hi myeloid cells or B220+ cells. These are the same recipients
used for 5 week- and 9 week- analyses in Figure 4c.

98

G. BM chimierism 10 months post transplantation into young recipients. These are the same
recipients used for 5 week- and 9 week- analyses in Figure 4c and 7 month analysis in Figure
5F.

Figure 6. In vivo transplantion of old donors in young recipients
A. Experimental scheme for transplantation of KSL cells from “old” donors into young recipients.
Old donors were either 5 months or ~20 months old; KRNxG7 and B6xG7 test cells were
always age matched in 2 different experiments. “Old” B6xG7 or KRNxG7 with a CD45 allele
other than CD45.2 was not available. Therefore rather than compete the old B6xG7 and
KRNxG7 KSL cells head-to-head in the same recipient as done in Figure 4 and 5, they were
each competed with an equal number of young congenic B6xG7 (Ly5.1) KSL cells.
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Chimerism index, calculated as shown, gives the contribution of B6xG7 or KRNxG7 KSL test
cells normalized to total cell output in the recipient.
B. PB chimerism index for 20 month old KRNxG7 and B6xG7 donors
C. PB chimerism index for 5 month old KRNxG7 and B6xG7 donors

Figure 7. Arthritic KSL cells downregulate surface TLR4 protein and are refractory to LPS
stimulation
A. Validation of α TLR4 antibody (clone MTS510). BM from TLR4-/- and B6 (Ly5.1) mice, which
are TLR4+/+ were stained with KSL markers as well as PE conjugated αTLR4 antibody.
Histogram indicates cell surface TLR4 protein expression by KSL cells
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B. Cell surface and intracellular TLR4 protein expression in arthritic (KRNxG7) and control KSL
cells. Isotype control staining is shown in red.
C. Experimental scheme for in vitro competitive culture of arthritic and control KSL cells. Arthritic
and control mice have different CD45 (Ly5) alleles. 5000 each of arthritic and control KSL
cells were mixed in the same well of a 24 well plate with survival cytokines, KitL+Flt3L and
media containing 10% serum with different concentrations of LPS.
D. Top: FACS plot depicting myeloid differentiation of KSL cells in vitro after 3.5 days of culture
with different doses of LPS. KRNxG7 KSL cells and B6xG7 KSL cells were used. Myeloid
cells (red gate) are Mac1+ and/or Gr1+ and negative for B cell (B220), T cell (CD3, TCRβ)
and Erythrocyte (Ter119) markers.
Bottom: FACS plot depicting chimerism analysis to determine arthritic KSL derived (Ly5.2+)
and control KSL derived (Ly5.1+) myeloid cells.
E. Top: Mac1/Gr1+B220-CD3-TCRβ-Ter119- frequency after in vitro competitive culture of
arthritic KSL cells (serum injected B6xG7 mice) and control KSL cells (PBS injected B6xG7
mice).
Bottom: Relative contribution of KSL cells to Mac1/Gr1+B220-CD3-TCRβ-Ter119- cells.
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Figure 8. Experimental scheme for determining the role of TLR4 in the myeloid priming
induced in KSL cells by arthritis
Bone marrow chimeric mice are generated from TLR4-/- and CD45 congenic wild type mice. This
is followed by serum arthritis induction of the chimeric mice after engraftment and steady state is
achieved (typically 6-8 weeks). TLR4-/- and TLR4+/+ KSL cells can then be sorted based on
different CD45 allele expression. Gene expression or Prospective differentiation assays can then
be performed with these cells.
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CHAPTER 5
DISCUSSION AND FUTURE DIRECTIONS
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SUMMARY OF MAJOR FINDINGS
While a lot is known about the behavior of primitive progenitors in physiological states,
the question of if and how these cells are affected by disease and how they in turn contribute to
the disease process has been minimally explored. The immune response to infectious and
inflammatory states has almost invariably been studied at the level of mature cells. In this study,
we have shown that bone marrow primitive progenitor frequency and cycling is unchanged in
arthritic mice although it is markedly increased in the spleen. Using in vivo transplantation, in vitro
differentiation and gene expression analyses of sorted cells, we have shown that primitive
progenitors including HSCs from arthritic mice are myeloid primed although they retain the
capacity to differentiate into other lineages. These cell intrinsic changes are environment
dependent because firstly, it is reversed when arthritic KSL cells are transplanted into young wild
type (B6xG7) environment and secondly, it can be triggered in KSL cells from normal B6 mice
induced to develop arthritis by arthritogenic serum transfer. This myeloid priming of arthritic HSCs
correlates with skewed myeloid frequencies at the committed progenitor and mature cell levels in
the arthritic mice.

DISEASE RELEVANCE
Role of primitive progenitor myeloid priming in disease
Myeloid cells including neutrophils, monocyte lineage cells and osteoclasts are crucial for
the joint specific inflammation and destruction as well as the systemic inflammation that occur in
arthritis [1-9]. Our findings that primitive progenitors in arthritic mice are myeloid primed suggests
that primitive progenitors are co-opted to facilitate disease. Even though mechanisms occurring at
the mature cell level such as increased survival [4, 10] undoubtedly contribute in prolonging
chronic arthritis, these cells have a finite life span and need to be eventually replenished.
Primitive progenitors including HSCs, which have self renewal ability, are myeloid primed in order
to meet this pathologic demand thus fueling disease. In fact we found that the transcription factor
Foxo3a which has been shown to promote arthritis by improving the survival of neutrophils is
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already increased in arthritic KSL cells. We propose that there is a positive feedback loop that
drives chronic disease; the inflammatory environment triggers myeloid priming and increased
myeloid output from primitive progenitors which in turn perpetuates the inflammation in a vicious
cycle.
The potential powerful role of HSCs and primitive progenitors in disease cannot be
underscored since a single HSC can reconstitute an entire hematopoietic system. However, how
do we show that HSCs or primitive progenitors indeed have a role to play in arthritis since these
cells do not transfer the disease when transplanted into naïve recipients? The most obvious
experiment to propose would be to selectively block myeloid priming in primitive progenitors, such
as by a Cre mediated conditional knockout or knockdown of cell intrinsic molecules required for
myeloid priming, and then assess the effect on disease outcome. There are a number of reasons
why this experiment is not trivial. First, no Cre mouse has been generated that is specific to
primitive progenitors. Mx-Cre and Vav-Cre mice that are currently used in HSC research will also
be functional in other hematopoietic and/or non hematopoietic lineages. Second, the target
molecule chosen should be one that does not also play a role in mature cells since these cells
derive from primitive progenitors. This can be ruled out by parallel experiments where the target
molecule is conditionally cleaved out using Cre molecules specific to mature cells such as Mac1Cre or LysozymeM-Cre. The cell intrinsic molecules driving myeloid priming are currently
unknown and it remains to be determined if molecules that facilitate disease at the primitive
progenitor level but not at the mature cell level exists. Selective manipulation of primitive
progenitors is important to rule out the possibility that amelioration of disease is due to changes at
the mature cell level.
We are currently establishing a system that will allow us to evaluate the role of primitive
progenitors in arthritis. We found that lethally irradiated mice were resistant to serum transfer
arthritis most likely because of the ablation of their hematopoietic system especially short-lived
neutrophils, which are required for arthritis initiation [1-4]. Lethally irradiated mice succumb to
irradiation after 10-14 days allowing a time window for short-term experiments. In these lethally
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irradiated mice we can transplant different cell types including primitive progenitors from wild-type
and mutant mice and evaluate their ability to restore arthritis susceptibility following serum
injection. Based on cell dose injected, volume of arthritogenic serum injected and disease
incidence and severity elicited we would be able to score the contribution of a cell to disease
induction.
We have found that a single injection of 20000 KSL cells (the only dose we have tried)
restored disease susceptibility in all mice injected with 150µl (the only dose we tried) of serum.
6

This in itself is significant because in previous studies, repeated injections of as much as 5x10 to
7

1x10 wild type BM or PB neutrophils per injection was needed to restore arthritis susceptibility in
mutant mice with defective neutrophils [2-4]; the ratio of KSL cells to neutrophils in the bone
marrow is about 1:100. Instead of irradiation, these neutrophil defective mice coud also be used
as recipients. Irradiation or neutrophil defective mice are better options than using an anti-Gr1
antibody whose lingering effects days after treatment [1] would block the action of de novo
generated neutrophils.

In situ involvement of primitive progenitors in arthritis
In addition to increased magnitude of myeloid cell output, there is also the need for
directionality with respect to joint disease. Rapid neutrophil infiltration into the joint following
arthritogenic serum transfer is well documented [1, 11]. However, it is not clear for instance what
the origin of osteoclasts in diseased joints are or whether like osteoclasts, some of the myeloid
cells including neutrophils are generated in situ in diseased joints. HSCs and progenitors are
known to circulate at low levels in peripheral blood and lymph transiting in and out of different
organs and tissues but the biological relevance of this phenomenon has remained obscure [1214]. Recently, Massberg et al showed that inflammatory signals mediated by Pertussis toxin or
LPS can interfere with Sphingosine-1-phosphate mediated egress of progenitors from
extramedullary sites and hence retain these cells at sites of inflammation [14]. Si et al have
consequently shown that intraperitoneal aseptic inflammation induced by thioglychollate injection
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recruits primitive progenitors including HSCs to the peritoneum [15]. In this study, we showed that
KSL cells are increased in the peripheral blood of arthritic mice and that these KSL cells are not
spleen derived because PB KSL frequency in asplenic arthritic mice is the same as in arthritic
mice with intact spleen. Furthermore, unpublished work from the lab (Yang et al) has shown that
CD45+Lin- cells are increased in arthritic joints; KSL cells could not be adequately evaluated
because tissue preparation involved prolonged incubation with collagenase and dispase which
has been shown to downmodulate cell surface Kit [16]. GFP labeled CD45+Lin- cells (from βactin::GFP mice) injected into arthritic mice are also selectively recruited to the joint (Junjie
Yang). These previous findings and ours raise the possibility that myeloid primed primitive
progenitors are recruited to arthritic joints where they may contribute directly to myeloid effector
cells including osteoclast by differentiating in situ.
In preliminary experiments, we have demonstrated that KSL cells from arthritic mice
injected into the ankle/foot of RANK-/- mice undergoing serum transfer arthritis were able to
develop into osteoclasts in situ without any added factors. RANK-/- mice were used because they
are completely devoid of endogenous osteoclasts due to a cell autonomous defect; RANKL is still
present to promote osteoclastogenesis of the transplanted progenitors. The contralateral
ankle/foot, which did not receive any KSL cells, were completely devoid of osteoclasts. This
system needs to be optimized. For example it is possible that there is an optimum time after
injection of serum when the joint environment is most likely to promote osteoclastogenesis. This
might be related to when RANKL is produced at the joint as well as when the relevant
endogenous osteoclast precursors traffic to the joint. An optimized system will for instance allow
comparison of in situ osteoclastogenic potential of circulating monocytes and bone marrow KSL
cells. It will also allow molecular manipulation of sorted KSL cells prior to joint injection to
determine which genes are mechanistically involved in in situ disease relevant joint
osteoclastogenesis.
We have also initiated 2-photon microscopy experiments to allow us to monitor the
trafficking of primitive progenitor to the joint based on imaging the toe of arthritic mice [17]. In this
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system, arthritis is induced by subcutaneous footpad injection of arthritogenic serum (Baomei
Wang). Arthritis that develops is initially confined to this foot although it eventually spreads to the
contralateral foot. During the period of unilateral arthritis, we can image the diseased foot with the
contralateral foot as a control. We were able to detect intravenously injected GFP+ Lin- cells
(from β actin::GFP mice) in the diseased joint, although this needs to be repeated. We found that
most injected cells were trapped in the spleen. Therefore, using asplenic Tlx1-/- mice in the future
might improve sensitivity of detecting injected cells at the joint. Improved sensitivity would allow
us to inject fewer cells allowing trafficking experiments of KSL and more enriched HSC
populations to be more feasible.
With this system, we can address the question of whether the degree of recruitment of
primitive progenitors versus mature cells at different times during the course of the disease is
different. Are mature cells like neutrophils initially recruited with a later arrival of primitive
progenitors? Also, based on the upregulation of molecules like Ccr2, MMP9 and P-selectin in
KSL cells from KRNxG7 arthritic mice, we can also address the question of whether primitive
progenitors from arthritic mice are recruited more robustly than primitive progenitors from nonarthritic mice. Test cells can be compared within the same recipients by obtaining cells from
transgenic mice with different fluorescent proteins (e.g. GFP and RFP) or by labeling cells with
fluorescent dyes like PKH-67 or CFSE and their different color variants. We can also determine if
primitive progenitors recruited to the joint generate mature effector cells in situ. One way of doing
this is to in vitro label KSL cells from Lysozyme M::EGFP with a red dye like PKH-26. Since the
lysozyme M promoter is very minimally active in KSL cells [18] these cells will be mainly red while
still in the primitive progenitor state. As they differentiate, the red dye becomes diluted out and if
they differentiate into neutrophils this would correspond to the emergence of green cells as a
result of the activation of the Lysozyme M promoter.
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MYELOID PRIMED PRIMITIVE PROGENITORS IN ARTHRITIS AND NORMAL AGING
KRNxG7 arthritic mice have a number of features that are reminiscent of normal aging.
These include weight loss, thymic atresia and low turnover osteoporosis, that is osteoporosis due
to diminished bone formation rather than overactive bone resorption [19]. Within the
hematopoietic system, we also find that KRNxG7 mice are mildly anemic, are lymphopenic and
have preferential myeloid output all of which occur in normal aging. KSL gene expression
analysis also revealed that upregulation of P selectin protein and IgH that occurs in aging
primitive progenitors also occurs in KRNxG7 arthritic primitive progenitors.
There are however some important dissimilarities between aged primitive progenitors and
arthritic primitive progenitors. Most prominently, some of the genes that were strikingly
upregulated in arthritic KSL cells including S100a8, S100a9 and Chi3l3 were all previously
reported to be downregulated in the normal aging of stem cells [20]. Furthermore, although
increased myeloid potential of arthritic and aged primitive progenitors are both epigenetically
induced, it appears the changes induced in the latter are more stable. In our own experiments
(Chapter 4: Figure 6), we found that old wild type (B6xG7) KSL cells in competition with young
wild type KSL cells still reconstituted the myeloid lineage better than lymphoid lineage (60%
versus 30%) 16 weeks post transplantation. On the other hand, when young arthritic KSL cells
were competed with young wild type KSL cells (Chapter 4: Figure 4), relative contributions to
lymphoid and myeloid lineages were the same as early as 9 weeks post transplantation. Recent
studies have suggested that normal aging is associated with the expansion of HSC clones
identified by high expression of CD150 [21]. However, we do not see clear differences in the
CD150 expression in the HSC enriched CD48- fraction of arthritic KSL cells compared with
control KSL cells. This may in part underlie the differences between arthritic primitive progenitors
and physiologically aged primitive progenitors. Interestingly, a recent study has also found that
even though mice with accumulating mitochondrial DNA mutations share several hematopoietic
features with physiological aging, there are still distinct differences [22, 23].
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As we gain a better understanding of the cell intrinsic molecular underpinnings of myeloid
priming in arthritic primitive progenitors, it will be interesting to discover how it converges and
diverges from the mechanisms of physiological aging. It will also be interesting to study what
aspects of the aged environment allow arthritic KSL cells to engraft better than control KSL cells
and maintain their myeloid primed output. It has been found for instance that HSCs with the same
phenotype located at different sites within the bone marrow have different lineage potentials [24].
Furthermore, primitive progenitors migration between niches within the bone marrow influences
myeloid versus lymphoid fate in vivo [25]. Therefore, it is possible that myeloid supportive niches
abound in aged mice and that these niches are preferentially occupied by arthritic KSL cells after
transplantation leading to the results we obtained.

TOWARDS THE STUDY OF PRIMITIVE PROGENITORS IN OTHER DISEASED STATES

Primitive Progenitor Identification in Non-Steady State – Altered markers or Altered
properties?
The use of fluorophore-conjugated antibodies to molecules expressed by cells, as is
extensively used in this study, has greatly facilitated the identification and sub-fractionation of
cells. This has proven indispensable in the prospective isolation and study of primitive progenitor
at steady state. However, since much of these molecular markers have been validated based on
cells at steady state, it cannot be guaranteed that the same cells in non-steady states will express
the same markers. As different cytokines, antigens or diseases may have different unpredictable
effects on primitive progenitors, it is important to confirm the applicability of the immunophenotype
used for isolation of primitive progenitors in the diseased/treated mouse.
A very relevant molecule in this regard is Sca1, one of the molecules used for identifying
“KSL cells”. Various molecules particularly Type I and II interferons are potent inducers of Sca1
[26-38]. Since hematopoietic progenitors express cell surface interferon receptors [39] microbial
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products or diseased states that induce interferon production upregulate Sca1 in hematopoietic
progenitors. This can lead to Kit+Sca1-Lin- committed progenitors masquerading as HSC
containing Kit+Sca1+Lin- (KSL) cells with concomitant depletion of phenotypic Kit+Sca1-Lincells. Very conspicuous Sca1 upregulation in hematopoietic progenitors, evident as a shift in a Kit
versus Sca1 FACS plot of Lin- gated cells, is observed in mice following infection with
Mycobacterium avium, Escherichia coli, Ehrlichia muris, Plasmodium chabaudi and Vaccinia virus
[39-43]. Even though these phenotypic changes are reported, the significance of this is not
acknowledged nor tested in the interpretation of the results of functional assays. Consequently,
expansion and increased cycling of phenotypic “KSL cells” (or subsets) is interpreted as
increased proliferation of HSC and primitive progenitors rather than due to the more numerous
and proliferative committed progenitors with altered phenoytpe. Defects in long term multilineage
reconstitution of irradiated recipients by these cells is interpreted as an HSC functional defect as
is seen in genetic knockouts that result in loss of HSC quiescence [44] rather than due to dilution
of true primitive progenitors by contaminating committed progenitors. Abolishment of these
properties in interferon receptor knockout mice is interpreted as a role for interferon in modulating
these properties rather than modulating Sca1 expression which is more likely. The inflammatory
stimulus, for example LPS, sometimes induce emigration of HSCs and/or increase in cellularity of
bone marrow in addition to Sca1 upregulation rendering whole bone marrow analysis inadequate
in evaluating functional changes due to the inflammatory stimulus. Therefore, Sca1 upregulation
may lead to internally consistent yet erroneous conclusions about primitive progenitor cell cycle
state, function and molecular mechanism of these changes in some diseased state.
The arthritis model we used in this study is free of these issues that have plagued
previous studies of primitive progenitors in non steady state. Arthritic KSL cells do not upregulate
Sca1 at the mRNA level and neither do we notice any Sca1 shift in FACS analysis reminiscent of
an immunophenotypic aberration. Cell cycling which is closely associated with the primitive status
of progenitors is unchanged in arthritic KSL cells and CD150+CD48-KSL cells relative to controls.
We show that although the arthritic KSL cells are myeloid primed they still retain a similar
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multilineage capacity as control KSL cells by virtue of their similar methylcellulose colony output,
mature cell output in non-competitive lymphogenic OP9 co-culture and restoration of a balanced
lineage output in long term transplantation experiments. In this regard we implicitly confirmed that
the KSL immunophenotype represents a bona fide primitive progenitor population as in control
mice free from Sca1 or other cryptic identification artifacts. Beyond examining KSL cells, we also
conducted gene expression analysis on CD150+CD48-CD34-KSL cells. At steady state, GMPs
are actually CD150-CD34+. This makes it even more unlikely that the myeloid priming we see is
due to GMPs masquerading as HSCs. This study shows that increased proliferation can be
dissociated from other inflammation driven effects on HSCs, such as myeloid priming, in contrast
with previous studies. Absence of HSC proliferation in inflammation does not imply HSC
homeostasis is not affected just as increased proliferation does not only occur in a setting of
inflammation.
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CHAPTER 6
EXPERIMENTAL PROCEDURES
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ANIMALS AND ANIMAL TREATMENT
Animals
a

b

C57BL/6 (B6; Ly5.2) and B6.SJL-Ptprc Pep3 /BoyJ (B6; Ly5.1) were purchased from
Jackson Laboratory and maintained in our suite. KRN TCR transgenic mice on a B6 background
g7/g7

(KRN; Ly5.2) and C57BL/6 congenic mice bearing arthritogenic I-A

MHC-II molecule (G7;

Ly5.2) [1] were both obtained from Dr. Paul Allen (Washington University) and maintained in our
suite. The G7;Ly5.1 strain was generated by crossing G7;Ly5.2 and B6;Ly5.1 mice first to
generate B6xG7 (Ly5.1xLy5.2), and then intercrossing F1s to generate G7;Ly5.1. B6xG7 mice
were generated from B6;Ly5.2 or B6;Ly5.1 crossed with G7;Ly5.2 or G7;Ly5.1 parents to get
mice with different Ly5 allleles - Ly5.1+Ly5.2-, Ly5.1+Ly5.2+, Ly5.1-Ly5.2+. G7 genotyping was
performed using a biotin conjugated anti – G7 antibody kindly provided by Dr. Emil Unanue
(Washington University). KRN, G7 and or B6xG7 mice, which are all non-arthritic were used as
controls in this study to arthritic KRNxG7 mice.
KRNxG7 were generated by crossing KRN mice with G7;Ly5.2 or G7;Ly5.1 mice to get
arthritic mice of different Ly5 isotypes – Ly5.1-Ly5.2+ and Ly5.1+Ly5.2+ respectively. We found
that placing food directly on the bedding of mouse cages drastically improved survival of KRNxG7
mice allowing some arthritic mice to attain a full lifespan. For the splenectomy experiment, mice
were sedated, followed by shaving and sterilization of the surgical site. The spleen was pulled
after making a small incision on the lateral skin. Vessels supplying the spleen were tied off and
both the abdominal cavity and skin were sutured. Splenectomy experiments were done with Julie
Ritchey a technician in Dr. John Dipersio’s lab at Washington University.
Tlx1-/- mice previously generated [2] was obtained from Dr. Qiufu Ma (Harvard
University). Genotyping primers for Tlx1 had to be redesigned since we found that published
primers [3] contained nucleotide differences with the mouse genome that impaired the accuracy
of genotyping results. For wild type Tlx1, forward primer: CTT CGG TAT CGA CCA GAT CC,
reverse primer CGG AGC CCC CGC CGC CGT AAG TG. For mutant Tlx1, published primers [3]
were used.
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TNFRI-/- and TNFRI, II double knockout mice were obtained from Dr. Steven Teitelbaum
(Washington University). MMP9-/- mice were obtained from Dr. Robert Senior (Washington
University). IL6-/- mice were purchased from Jackson Laboratories. For generation of KRNxG7
mice deficient in specific genes (X), homozygous knockout mice (X-/-) were bred with KRN and
G7 to obtain double heterozygotes (X+/-KRN+/- and X+/-G7+/-). Siblings were crossed to
generate homozygous knockouts of the gene of interest with G7 homozygotes or with the KRN
transgene (X-/-KRN+ and X-/-G7). These were then bred together to generate X-/- KRNxG7
mice. This complicated mating scheme had to be undertaken because KRNxG7 mice are non
sterile precluding simply crossing these mice with X-/- mice. With the exception of TNFRI-/- and
Tlx-/-, we failed to obtain KRNxG7 with homozygous knockouts of the other genes. For unknown
reasons, generation of X-/- mice that were also KRN+ or the fertility of these mice was the major
bottle neck in generating KRNxG7 X-/- mice.

Arthritis Transfer Models
a

b

C57BL/6 (B6; Ly5.2) or B6.SJL-Ptprc Pep3 /BoyJ (B6; Ly5.1) were given a single
intraperitoneal injection with 250µl of K/BxN arthritogenic serum (obtained from Dr. Paul Allen).
Mice 7 days post serum transfer were used for experiments – hematopoietic frequency analysis
or KSL sort for qRT-PCR experiments. Development of arthritis was confirmed visually and by
measurement of ankle thickness. Arthritis development was variable and not as robust as arthritis
in the KRNxG7 spontaneous chronic model. Based on past literature that arthritis severity occurs
in a distal to proximal manner and our observation that some mice had toe/finger swelling without
wrist swelling, we scored joint inflammation clinically as follows: Toe/Finger swelling = 1 point,
Ankle/Wrist swelling = 2 points. Scores for each of 4 limbs are then added together to give a
maximum score of 8 (most severe). Such a score is similar to what has been published before.
The cohort of mice that were used for the frequency analysis had scores of 2,6,7 out of 8.
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We found that a booster injection of 200µl of arthritogenic serum injected on day 2 led to
more robust and uniform joint swelling. Therefore, this 2-dose regimen was used in the
experiments to assess in vitro potential of sorted KSL cells.
For T cell transfer arthritis experiment, splenocytes of Cα B6xG7 mice [4] transplanted
with KRN T cells polarized in vitro by Th17 promoting conditions [5] and control non-transplanted
Cα B6xG7 were obtained and analyzed for KSL cells. We also found that transplantation of 1-2 x
6

10 splenocytes from KRN mice also induced disease in Cα B6xG7 mice. This would be used in
future experiments.

Mouse Antibody Treatment
300µg of Anti Murine TNFα antibody (TN3-1912) or Anti GST control antibody (both kind
gifts from Dr. Robert Schreiber, Washington University, St. Louis) was injected every 6 days from
20 days of age. Mice were analyzed at 6 weeks old.

Tissue Preparation
Mice were sacrificed by cervical dislocation or CO2 asphyxiation. If peripheral blood (PB)
analysis was to be performed, PB was collected prior to sacrificing mice by retro-orbital bleeding
into buffer containing 4% Bovine Serum and 0.1-0.2% heparin in phosphate buffered saline (PBS)
using heparinized capillary tubes.
Bone marrow was collected from tibia(e) and/or femur(s) by flushing using 25 gauge
needles as previously described [6] or by brief high speed centrifugation of bones longitudinally
aligned in a perforated eppendorf tube. Spleen was crushed between 2 glass slides or by
crushing with the plunger of a 5ml syringe onto a 40µm nylon filter (BD). Inguinal, brachial and/or
axillary lymph nodes were retrieved from mice and crushed between glass slides.
BM, PB or spleen cells were RBC lysed using RBC lysis buffer (Roche) or antibody
stained for magnetic sorting without RBC lysis as described below. Peripheral blood was
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subjected to 2 rounds of RBC lysis due to abundant red blood cells. Cellularity (of marrow or
spleen) were always determined after RBC lysis and hence do not account for RBCs. Residual
RBCs (low forward and side scatter) were also gated out during FACS analysis. Lymph nodes
were not subjected to RBC lysis since they contain very few RBCs.

FLOW CYTOMETRY
General Flow Cytometry
For progenitor cell sorting, mature cells were initially depleted from whole bone marrow
by magnetic sorting using the MACS lineage depletion kit (Miltenyi) and LS columns (Miltenyi).
6

Bone marrow from 2 tibiae and 2 femurs (about 50x10 cells) were incubated with 40µl of lineage
antibody cocktail followed by 80µl of microbead conjugated anti-biotin antibody. For antibody
staining, cells were typically incubated with antibodies in phosphate buffered saline (PBS)
containing 4% serum. Staining was usually performed in 96-conical well plates. Staining was
performed in eppendorfs when analyzing very small cell numbers (e.g. staining cells produced in
in vitro stromal cell free cultures). Incubation was typically for 15-20 minutes in the dark at 4°C.
Antibodies used in this study are listed in Table 1.
Magnetic sorting does not completely deplete Lin+ cells especially for arthritic mice,
probably because the Lineage antibody cocktail formulation is tailored to lineage frequencies
present in control mice which are different from those in arthritic mice. Therefore, we stained
lineage-depleted bone marrow with fluorophore conjugated antibodies to lineage markers to allow
gating out of residual Lin+ cells during FACS analysis. Lineage antibodies used were α-Ter119
(for erythrocytes), α-B220 (for B cells), Mac1 and Gr1 (for myeloid cells) and CD3, CD4, CD8
and/or TCRβ (for T cells). We found that a number of T cells in KRNxG7 mice lacked expression
of CD4 or CD8 but were still CD3+TCRβ+ identifying them as T cells. This is possibly due to
aberrant T cell development caused by the transgenic KRN TCR as previously reported [7, 8].
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The utilization of CD3 and/or TCRβ was especially important in progenitor (CD45+Lin-)
identification in the PB, spleen and lymph node. KSL analysis was not affected because these T
cells lack Kit expression.
α-IL-7Rα was always added to lineage cocktail for GMP sorts and most of the time for
KSL sorts to ensure that the KSL or GMP gates excluded committed lymphoid progenitors.
“Natural Helper Cells” which are non progenitor lymphoid clusters located in adipose tissue that
provide cytokine help for antibody production and self-renewal of B1 cells are also Kit+Sca1+Linbut express IL7Rα [9]. These cells were also stained with fluorophore conjugated progenitor
marker antibodies: α-Kit, α-Sca1, α-FcgR.
For IgG FACS FcγR blocking prior to and during antibody staining was performed to rule
out the possibility of non-covalent FcγR-IgG interaction as the source of the signal. Cells were
incubated in 1µg of purified unconjugated FcγR blocking antibody (Clone 2.4G2 from BD or Clone
93 from Biolegend) per 50µl of 4% serum/PBS for 5-10 minutes. 50µl of a 2X solution of
fluorophore conjugated antibodies also containing 1µg of FcγR blocking antibody was then added
to the cells followed by the typical 15 minute incubation at 4°C. Data is reproduced for KSL cells
from several young mice and both old (22 months) mice analyzed. Isotype control antibodies was
sometimes utilized for weak protein expression signal such as during IgG or TLR4 analyses of
KSL cells.
Analysis was performed on a FACScalibur (BD) and modified FACScans (BD) with 2 and
5

3 lasers capable of 5 and 8 color analyses respectively. For BM KSL analysis, 1x10 live cells are
typically analyzed during flow cytometry. When the estimated progenitor frequency is quite low
such as PB and spleen KSL frequency or analysis of purified BM HSC populations (such as
5

6

CD150+CD41-CD48- cells), 2x10 to 1x10 cells were typically analyzed. Data was analyzed
using FlowJo software (Treestar). Cell sorting for subsequent functional or gene expression
analysis was perfored with a MoFlo (Dako). Purity of KSL sorting was about 95% determined by
post sort analysis.
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Cell Cycle and Apoptosis Analyses
For 5-Bromodeoxyuridine (BrdU) analysis, KRNxG7 arthritic mice and age matched
control mice were injected intraperitoneally with a single dose (1 mg per 6 g of body mass) of
sterile-filtered BrdU (Sigma-Aldrich) dissolved in PBS. Mice were killed 2 to 3 hours later and BM
cells harvested as described earlier. Harvested BM cells were subjected to MACS lineage-cell
depletion (Miltenyi Biotec) described earlier and lineage depleted cells stained with α-Kit-FITC
(eBioscience), α-Sca1-PE and Streptavidin-PerCP-Cy5.5 (BD Biosciences PharMingen). Cells
were subsequently fixed, permeabilized and intracellularly stained with APC-conjugated α-BrdU
antibody using the APC-BrdU flow kit (BD Biosciences PharMingen). Data was collected using
the BD FACScalibur and data analyzed using BD CellQuest software.
For Ki67 analysis, MACS lineage depleted cells (described above) were surface stained
with antibodies α-Kit APC-eFluor 780, α-Sca1-PE, α-CD150-APC. PerCP-Cy5.5 conjugated
IL7Rα, CD48, and lineage antibodies were used to minimize the number of channels for analysis
of CD150+CD48-KSL cells. Cells were then fixed and permeabilized using BD cytofix/cytoperm
solution. Fixed cells were then incubated with Ki67 FITC antibody (BD) or FITC conjugated
isotype control antibody for 30 minutes at 4°C.
For apoptosis, we used Cy3 conjugated Annexin V antibody (Biovision). After KSL
staining, cells were incubated with Annexin V buffer containing Annexin V according to
manufacturer’s instructions.

GENE EXPRESSION ANALYSIS
Microarray and Bioinformatics Analysis
Total RNA was extracted and purified from FACS sorted CD45+KSL cells and RBC lysed
Lin+ fraction of MACS sorted bone marrow using Arcturus Picopure RNA kit (Applied
Biosystems). 3 strains were used – KRNxG7 arthritic mice, KRN non-arthritic control mice and
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B6xG7 non-arthritic control mice. Therefore, there were 6 samples in total. For each strain, KSL
cells and Lin+ cells were from 7-9 pooled mice. All mice were age matched (6-7wks). 3.7x10
5

5

5

6

B6xG7 KSL, 4.7x10 KSL, 7.4x10 KRNxG7 KSL and 1x10 Lin+ cells from each strain were used
for RNA extraction. Purified RNA was linearly amplified and RNA from all 6 samples run on an
Affymetrix Mouse 430 2.0 gene chip. Linear amplification and microarray were carried out at the
Affymetrix core facility at Washington University School of Medicine
http://www.pathology.wustl.edu/research/lcglab/lcgexp.php
Microarray raw data was extracted and analyzed using dChip software
(http://www.biostat.harvard.edu/complab/dchip/) with the help of Jason Mills (Washington
University). “Upregulated genes” are at least 20% increased in arthritic KSL cells relative to both
control KSL cell populations (from B6xG7 and KRN – both non-arthritic) examined in this study.
Similarly “downregulated genes” were at least 20% reduced relative to both control KSL
expression levels.
Clustering analyses comparing gene chips from this study to each other and other stem
cell and mature cell populations from previous studies were carried out using GOurmet software
[10, 11] with the help of Jason Mills (Washington University). Briefly, average expression of
various genes in mature cells was determined from the 3 Lin+ microarray results using dChip.
Lists of genes enriched in each KSL population relative to mature cells were then determined by
comparing raw expression in the KSL population with the predetermined average expression of
the mature cells. Fractional representation of GO terms associated with each gene list was
calculated and then each cell population was then compared with previous gene expression
studies at the level of the GO term representation (See Table 2).
DAVID online resource [12-14] was used for other bioinformatics analysis particularly
functional annotation of differentially regulated genes.
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Quantitative Real Time PCR
For qRT-PCR analysis of total marrow hematopoietic and non-hematopoietic cells, nonadhered marrow cells were initially flushed out with buffer pelleted and saved. Adhered marrow
cells were retrieved and simultaneously lysed by infusing marrow cavity with 1ml of trizol reagent
(Invitrogen). This same solution was also used to lyse non-adhered marrow cells. Trizol
containing whole marrow cell lysates was stored at -80°C.
Primitive progenitors (KSL cells or CD150+CD48-CD34-KSL cells) were sorted directly
into trizol. Since HSC expression of CD34 changes during ontogeny (from CD34+ in fetal liver
HSCs to CD34- in adult mice) [15], we used mice that were 14-15 weeks old. 10000 to 20000
KSL cells per mouse were collected. 3 independent arthritic mice and 3 independent control mice
were used. For CD150+48-CD34-KSL cells, 3 independent pools each from arthritic and control
mice were used; each pool contained cells from 2 mice. 4000 to 7000 cells per pool were
collected and used for RNA extraction. For each experiment (KSL or CD150+CD48-CD34-KSL)
sorting from all mice was performed on the same day ensuring exact same gates were used.
Collected cells in trizol were vortexed and stored at -80°C.
RNA extraction and purification was performed according to manufacturers instruction for
trizol with the exception that linear acrylamide (Ambion) was used as a carrier for RNA extraction
from primitive progenitors. For whole marrow, we used 1µg of RNA in subsequent steps. For
primitive progenitors, we estimated RNA yield to be less than 1µg. Therefore all RNA extracted
was used in subsequent steps. Purified RNA was subjected to DNAse digestion followed by first
Strand cDNA synthesis using Superscript III reverse transcriptase (Invitrogen). cDNA obtained
was diluted in autoclaved distilled water and qRT-PCR performed with Sybr Green as done
previously [6, 16]. QRT-PCR primers used in this study are listed in Table S3.
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IN VITRO ASSAYS
Methylcellulose Colony Formation
hi

KSL cells or GMP enriched cells (Kit+Sca1-Lin-IL-7Rα-FcγRIII/II ) from 6-9 week old age
and sex-matched (male) arthritic and control mice were sorted on a MoFlo as described above.
KRN, G7 or B6xG7 mice were used as controls. Granulocyte and Macrophage (GM) restricted
(HSC 008; R & D) and Erythroid restricted (Methocult SF M3436; Stem Cell Technologies)
methylcellulose based media were used for replating according to product information sheet with
minor modifications. Each population (KSL or GMP) from each mouse was plated in duplicate.
200 cells per plate were used for replating on GM-restricted plates. KSL cells formed much fewer
colonies in erythroid restricted plates and hence 1000 cells per plate was used. GM colonies were
enumerated on day 7-10 while erythroid colonies were enumerated on D14. Colony counts were
performed in a blinded manner to determine mean colony counts, based on duplicates, for each
mouse which were then used in subsequent statistical analysis. Plating efficiency was calculated
as (number of colonies/number of progenitor cell input) x 100. Data for colony formation on
complete media is not shown but was similar to colony formation on GM-restricted media.

In vitro stromal cell free culture
Sorted KSL cells from arthritic and control mice were mixed in 1:1 ratio (5000 cells each)
and cultured in 24 well tissue culture plates (TPP). Culture media consisted of StemSpan serum
free base medium (Stem Cell Technologies), 10% serum (Hyclone), KitL (1% supernatant) and
Flt3L (Peprotech or Ebiosciences). Cells were incubated at 37°C with 5% CO2. 3.5 days later,
cells were harvested for analysis. Control mice were Ly5.1+ or Ly5.1+Ly5.2+ while arthritic mice
were always Ly5.2+. Experiments were performed in 2 sets (N=3 in each set).
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Osteoclast In vitro assay
Osteoclast culturing media consisted of α10 media (α-MEM + 10% serum + Penicillin &
Streptomycin antibiotics), 10% CMG supernatant, as a source of M-CSF, and RANKL. RANKL
was typically used at 100ng/ml although different concentrations were also tried. All reagents
were obtained from the Teitelbaum lab (Washington University).
Two thousand sorted KSL cells or GMP cells were cultured in 96 well flat bottom plates
containing 200µl of osteoclast culturing media. Half the media was changed with fresh media on
Day2 and daily thereafter. Plates were fixed on Day 5-9 with 4% paraformaldehyde and stained
with a histochemical TRAP staining kit (Sigma). GMP cells from arthritic or control mice that were
at least 6 weeks of age robustly and consistently generated osteoclasts in vitro and thus were
used as a positive control.
Note that typical protocols for generating osteoclasts in vitro involve priming whole bone
marrow by culturing with M-CSF for about 3 days to generate so called “bone marrow
macrophages”. These are then subsequently cultured with M-CSF and the indispensable
cytokine, RANKL, to generate mature osteoclasts in about 5 more days. However to test
osteoclast potential of specific cell populations, the sorted cells are cultured with M-CSF and
RANKL immediately without the need for initial priming with M-CSF.

Differentiation on OP9 stromal cells
Three thousand sorted KSL or GMP cells were cultured on irradiated OP9 cells in 6 well
plates. In some experiments, 1000 cells were cultured in 24 well plates. Cells were grown in
αMEM with 10% serum 10 KitL (1% of supernatant), 10ng/ml IL-7 (Peprotech) and 20ng/ml Flt3L
(Peprotech). After 5-8 days, cultured cells were recovered by vigorous resuspension, stained with
fluorescent conjugated antibodies and FACS analyzed. Vigorous resuspension, as opposed to
enzymatic digestion, was used to recover cells from culture, since enzymatic digestion could at
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times lead to destruction of epitopes for antibody recognition for FACS analysis. Approximately,
90% or more of the cells were recoverable by vigorous resuspension.

IN VIVO ASSAYS
General Competitive Transplantation
Recipient mice were lethally irradiated (10Gy; single dose) a day before cell
transplantation. Lethally irradiated mice were administered antibiotic treated water – changed
twice weekly - for 3 weeks following irradiation. Sorted cells were pelleted and resuspended in
HBSS and a 200µl volume of suspension was transplanted via the tail vein. For competitive
transplantation, cell suspensions from 2 competing strains were mixed at the appropriate
concentrations and injected in the same 200µl volume. Effectiveness of irradiation was verified by
death of non-transplanted irradiated mice less than 2 weeks after irradiation and markedly low
chimerism of recipient derived cells in transplanted mice.
We were unable to track erythroid chimerism because mature erythroid cells do not
express CD45 and erythroid precursors have very low to no CD45 expression. Even though T cell
chimerism analysis was possible, these results do not reflect T lineage potential because
KRNxG7 derived T cells, which express autoreactive KRN TCR, are negatively selected in the
recipient mice [1, 6]. The elimination of arthritic KSL derived T cells also makes it impossible to
determine overall CD45 chimerism of arthritic versus control KSL cells although contribution to
individual lineages can be assessed.

Young Recipient Competitive Transplantation – Supplemental Information
Preliminary analysis showed hardly any leucocytes in peripheral blood at very early time
point (10 days or less) post transplantation. Therefore for D6 time point only bone marrow was
analyzed. In fact total cell count of RBC lysed bone marrow retrieved from 2 tibiae and 2 femurs
5

of recipient mice 6 days after transplantation was about 2x10 cells, about 200 fold lower than
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typical cellularity of unirradiated mice. At this early time point B220+ cells were also hardly
existent in the bone marrow. By 16 days post transplantation, bone marrow cellularity had largely
7

recovered with cell count of close to 3x10 . Mice used for 6 day- (N=4) and 16 day- (N=4)
analyses were sacrificed in order to analyze bone marrow. Peripheral blood from remaining
recipient mice from the same transplant cohort (N=4) was sampled non-lethally at subsequent
time points (5wks, 9wks).

Old Recipient Competitive Transplantation – Supplemental Information
For transplantation into old recipients, 5 recipient mice were used. One failed to engraft
donor cells appreciably and was therefore excluded from mean and standard deviation analyses
presented in Figure 6B. Nevertheless, this mouse still displayed the same pattern of higher
myeloid cell output from arthritic KSL cells. 8wks post transplant Mac1+Gr1hi cells comprised
70% of PB, higher than the other mice in the cohort. Most (>95%) of these Mac1+Gr1hi cells
were recipient derived while 3.15% (99% of total donor derived cells) was arthritic KSL derived
and only 0.026% (1% of total donor derived cells) were control KSL cell derived. On the other
hand, in this same mouse, B220+ frequency at 8wks (11.4%) was lower than the other mice in
the cohort, with the majority of these cells coming from control KSL cells (84.5% of all, 95% of
donor derived cells). Only 4.2% of the B220+ cells (5% of donor derived cells) came from arthritic
mice. This and another recipient died before the 26wk analysis time point. Therefore, 8wk and
16wk analysis was performed with N=4 recipients while 26wk analysis was performed with N=3
recipients. In general, recipient mice were more variable than young recipient mice with respect to
contribution from residual recipient cells probably reflecting reduced sensitivity to irradiation.

In situ Osteoclast Differentiation of KSL cells
3 week old RANK-/- mice generated from RANK+/- heterozygotes were given serum
transfer arthritis by 2 injections of arthritogenic K/BxN serum at 10µl/g body mass. Sorted KSL
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cells were resuspended to a concentration of 20000-30000 cells/10µl of HBSS. 30µl of
suspension was injected subcutaneously on the dorsal side of the foot into the ankle.

STATISTICS
Student t-test was used to determine statistical significance for all quantitative data. Bar
graphs and error bars representing mean and standard deviation respectively are used to display
quantitative data based on multiple mice. * = p< 0.05; **=p<0.01; ***=p<0.001.

TABLES ASSOCIATED WITH EXPERIMENTAL PROCEDURES
Table 1. Antibodies used in this study
Molecule
Kit
Sca1
CD3
CD4
CD4
CD8
TCRb
B220
Mac1
Gr1
Ly6G
cFms
Ly6C
Ter119
IL-7Ra
FcgR III/Iib
FcgR III/Iib
CD34
CD150
CD48
CD11c
CD45
CD45.1
CD45.2

Clone
2B8
D7
145-2C11
GK1.5
RM4-5
53-6.7
H57-597
RA3-6B2
M1/70
RB6-8C5
1A8
AFS98
AL-21
Ter119
A7R34
2.4G2
93
RAM34
TC1512F12.2
HM48-1
N418
30-F11
A20
104

Source
Biolegend, Ebioscience
BD, Biolegend, Ebioscience
Biolegend, Ebioscience
BD, Biolegend, Ebioscience
Ebioscience
Biolegend, Ebioscience
Biolegend
Biolegend, Ebioscience
BD, Biolegend, Ebioscience
BD, Biolegend, Ebioscience
Biolegend
Biolegend, Ebioscience
BD
Biolegend, Ebioscience
Ebioscience, Biolegend
BD
Biolegend
Ebioscience, BD
Biolegend
Biolegend, Ebioscience
Biolegend
BD, Biolegend, Ebioscience
Ebioscience, Biolegend
Ebioscience, Biolegend
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CD71
CD71
NK1.1
Streptavidin
Lineage cocktail

C2
R17217
PK136

BD
Ebioscience
BD
BD, Ebioscience
Miltenyi

Table 2. References for gene chips used for dendrogram analysis.
Name
Mature Skin
Mature Hematopoietic Cells 1
Mature Gastric Cells 1
Mature Small Intestine
Brain
Mature Gastric Cells 2
Mature Gastric Cells 3
Mature Hematopoietic Cells 2
Mature Hematopoietic Cells 3
Neural Progenitors
Neural Progenitors
Gastric Progenitors
Mesenchymal Progenitors
Small Intestine Progenitors
Skin Progenitors
Hematopoietic Progenitor 4
Hematopoietic Progenitor 1a
Hematopoietic Progenitor 1c
Hematopoietic Progenitor 1b
Hematopoietic Progenitors 2
Hematopoietic Progenitors 3

Reference
[17]
This Study
[18]
[19]
[20]
[21]
[18]
[20]
[22]
[20]
[22]
[23]
[24]
[25]
[26]
[27]
This Study
This Study
This Study
[20]
[22]
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Table 3. Quantitative RT-PCR primers used in this study
Gene
C/EBPb
C/EBPb
Ccr2
Ccr2
Chi3l3
Chi3l3
Ear1
Ear1
EKLF (Klf1)
EKLF (Klf1)
FcgrIIb
FcgrIIb
FcgrIII
FcgrIII
Fog1 (Zfpm1)
Fog1 (Zfpm1)
Gata1
Gata1
Ikaros
Ikaros
Mpa2l
Mpa2l
PU.1
PU.1
Runx1
Runx1
S100a8
S100a8
S100a9
S100a9
SOCS3
SOCS3
VWF
VWF

Primer Sequence
AAGCTGAGCGACGAGTACAAGA
GTCAGCTCCAGCACCTTGTG
ATCCACGGCATACTATCAACATC
CAAGGCTCACCATCATCGTAG
AGAAGGGAGTTTCAAACCTGGT
GTCTTGCTCATGTGTGTAAGTGA
CTGTTGGTGTGTGTGGAAATCC
ATTTGTTGCCCGACTGGTGAT
AGACTGTCTTACCCTCCATCAG
GGTCCTCCGATTTCAGACTCAC
ATGGGAATCCTGCCGTTCCTA
CCCAGCAGCAAGATTTAGCAC
TCACTGTCCAAGATCCAGCAA
CGGGGTTTGAAGATTTCTCCGTA
CAGAGCCTTATCCCCTGAGAG
CGGCTTCTTCAGTTAGGACCT
ATGGAATCCAGACGAGGAAC
CTCCCCACAATTCCCACTAC
AGACAAGTGCCTGTCAGACAT
CCAGGTAGTTGATGGCATTGTTG
GTTCCAGGAAGTAACAAAGGCT
ATCCCTAGTCTATTCCCAGTGAC
GAACAGATGCACGTCCTCGAT
GGGGACAAGGTTTGATAAGGGAA
CTTCCTCTGCTCCGTGCTA
CTGCCGAGTAGTTTTCATCG
AAATCACCATGCCCTCTACAAG
CCCACTTTTATCACCATCGCAA
ATACTCTAGGAAGGAAGGACACC
TCCATGATGTCATTTATGAGGGC
CAAGAACCTACGCATCCAGTG
CCAGCTTGAGTACACAGTCGAA
CTTCTGTACGCCTCAGCTATG
GCCGTTGTAATTCCCACACAAG
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Amplicon
Size (bp)
116
104
109
119
165
117
137
107

110
102
107

165
129
101
125
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